0001144204-13-052978.txt : 20131224 0001144204-13-052978.hdr.sgml : 20131224 20130930110024 ACCESSION NUMBER: 0001144204-13-052978 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 8 CONFORMED PERIOD OF REPORT: 20130927 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130930 DATE AS OF CHANGE: 20130930 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRANSGENOMIC INC CENTRAL INDEX KEY: 0001043961 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 911789357 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30975 FILM NUMBER: 131121899 BUSINESS ADDRESS: STREET 1: 12325 EMMET ST CITY: OMAHA STATE: NE ZIP: 68164 BUSINESS PHONE: 4027385480 MAIL ADDRESS: STREET 1: 12325 EMMET STREET CITY: OMAHA STATE: NE ZIP: 68164 8-K 1 v356113_8-k.htm CURRENT REPORT

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

September 27, 2013

 

TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)
     
Delaware   000-30975
(State or other jurisdiction of incorporation)   (Commission File Number)
     
91-1789357
(IRS Employer Identification Number)
     
12325 Emmet Street
Omaha, NE
  68164
(Address of principal executive offices)   (Zip Code)
     
(402) 452-5400
(Registrant’s telephone number, including area code)
 
Not applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

£Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

£Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

£Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

£Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e(c))

 

 
 

  

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Termination of Craig J. Tuttle

 

On September 27, 2013, the Board of Directors (the “Board”) of Transgenomic, Inc. (“Transgenomic”) notified Mr. Craig J. Tuttle, President and Chief Executive Officer of Transgenomic and a member of Transgenomic’s Board of Directors (the “Board”), that his employment with Transgenomic was terminated, effective immediately. On September 30, 2013, Mr. Tuttle resigned from the Board, effective immediately. Mr. Tuttle’s decision to resign from the Board was not due to any disagreement with Transgenomic on any matter relating to Transgenomic’s operations, policies or practices. Pursuant to his employment agreement with Transgenomic, Mr. Tuttle will receive severance pay in the amount of $350,000, payable in installments over 12 months in accordance with Transgenomic’s payroll practices.

 

Appointment of Paul Kinnon as Chief Executive Officer and President and a Director

 

On September 30, 2013, Transgenomic announced that the Board appointed Paul Kinnon to the Board and to succeed Mr. Tuttle as Chief Executive Officer and President of Transgenomic, effective as of September 30, 2013.

 

Mr. Kinnon, age 50, has more than 20 years of global leadership experience in innovative life science and diagnostics companies. From January through August 2013, he provided consulting services to the life science sector as a Partner at Arch Global Research. During a portion of this time, Mr. Kinnon provided consulting services to Transgenomic. From January 2007 to December 2012, Mr. Kinnon was President, CEO and a Director of ZyGEM Corporation Limited, a biotechnology company, where he transformed the company from a regional enzyme provider into a leader in integrated microfluidic technologies for forensic and clinical diagnostic applications. From May 2006 to June 2007, Mr. Kinnon was Vice President & General Manager Environmental Diagnostics (later expanded to Applied Markets) at Invitrogen Corporation (now Life Technologies), a high growth life sciences and diagnostics firm, and from October 2004 until April 2006, he was Vice President, Global Strategic Alliances at Invitrogen. Previously, Mr. Kinnon also held business, sales and marketing roles of increasing responsibility at Guava Technologies, Inc., Cellomics, Inc. and other life science companies. Mr. Kinnon earned his Bachelor of Sciences degree in Applied Chemistry at Coventry University in the United Kingdom and holds a Diploma of Marketing. The Board selected Mr. Kinnon to serve as a director because he is Transgenomic’s Chief Executive Officer and President, which creates a critical link between management and the Board, enabling the Board to perform its oversight function with the benefits of management’s perspectives on our business. In addition, Mr. Kinnon’s prior leadership, extensive business and operating experience, and deep understanding of our technologies and markets, is extremely valuable to the Board.

 

Transgenomic entered into an employment agreement with Mr. Kinnon, dated September 27, 2013 (the “Employment Agreement”), whereby he was appointed Chief Executive Officer and President of Transgenomic effective as of September 30, 2013. The Employment Agreement provides that Mr. Kinnon will be employed by Transgenomic for a period of one year, subject to automatic renewal for additional one-year periods unless terminated by either party upon written notice to the other at least three months prior to the subsequent one-year term. Under the terms of the Employment Agreement, Mr. Kinnon will be paid an initial base salary of $350,000 per year. His base salary will be reviewed by the Compensation Committee of the Board for an increase on at least an annual basis and may be adjusted at any time in the Compensation Committee’s sole and absolute discretion, provided that any decrease in base salary must either be with Mr. Kinnon’s written permission, or be part of an across-the-board reduction that affects all senior executives of Transgenomic by the same percentage. Commencing January 1, 2014, Mr. Kinnon will be eligible to receive an annual bonus based on his performance under agreed upon goals, objectives and formulas, provided that his target bonus for any year shall not be less than 40% of his then-current base salary. The Employment Agreement contains standard confidentiality, noncompetition and nonsolicitation provisions and provides for a severance payment to Mr. Kinnon equal to 12 months of Mr. Kinnon’s then-current base salary if he is discharged without “Cause” (as defined in the Employment Agreement), other than due to Mr. Kinnon’s disability, or if Mr. Kinnon resigns for “Good Reason” (as defined in the Employment Agreement), in each case provided that Mr. Kinnon executes a severance agreement and general release in favor of Transgenomic. The Employment Agreement also provides that Transgenomic will reimburse Mr. Kinnon for certain expenses associated with commuting from Solana Beach, California to Transgenomic’s offices in Omaha, Nebraska and New Haven, Connecticut. The Employment Agreement further provides that the vesting of the equity awards granted by Transgenomic to Mr. Kinnon described below, as well as all future equity awards granted to Mr. Kinnon by Transgenomic, will accelerate in full and become fully vested upon a Change in Control, as defined in the Transgenomic 2006 Equity Incentive Plan (the “2006 Equity Plan”).

 

 
 

 

Pursuant to the Employment Agreement, Mr. Kinnon will be granted an option to purchase 2,150,000 shares of Transgenomic’s common stock (the “Option”) with an exercise price equal to the fair market value of one share of Transgenomic’s common stock on the date of grant, which will be October 4, 2013. The Option will be granted pursuant to the 2006 Equity Plan and a stock option agreement (the “Option Agreement”). One-third of the shares subject to the Option will vest on the first anniversary of the date of grant, with the remaining shares vesting in 24 substantially equal installments thereafter, subject to Mr. Kinnon’s continued employment with Transgenomic on each such date. If Transgenomic terminates Mr. Kinnon’s employment without Cause or Mr. Kinnon terminates his employment for Good Reason prior to October 4, 2014, one-third of the shares subject to the Option will be deemed automatically vested. The Option will accelerate in full and become fully vested upon Mr. Kinnon’s death, disability or retirement provided that he has continuously served as a director, employee or advisor of Transgenomic for the two-year period immediately preceding such event.

 

The Employment Agreement also provides that Mr. Kinnon will be granted stock appreciation rights (“SARs”) with respect to 1,000,000 shares of Transgenomic’s common stock with an exercise price equal to the fair market value of one share of Transgenomic’s common stock on the date of grant, which will be October 4, 2013. Thirty-four percent of the shares subject to the SARs will vest on the first anniversary of the date of grant, with the remaining shares subject to the SARs vesting ratably over the remaining 24 months, subject to Mr. Kinnon’s continued employment with Transgenomic on each such date. If Transgenomic terminates Mr. Kinnon’s employment without Cause or Mr. Kinnon terminates his employment for Good Reason prior to October 4, 2014, 34% of the SARs shall be deemed automatically vested. The SARs will accelerate in full and become fully vested upon Mr. Kinnon’s death, disability or retirement if he has continuously served as a director, employee or advisor of Transgenomic for the two-year period immediately preceding such event. The SARs will be granted pursuant to the 2006 Equity Plan and a SARs agreement (the “Kinnon SARs Agreement”). Upon exercise of the SARs, Mr. Kinnon will be entitled to receive shares of Transgenomic common stock or cash, subject to the terms of the Kinnon SARs Agreement.

 

The foregoing descriptions of the Employment Agreement, the Option Agreement and the Kinnon SARs Agreement do not purport to be a complete description and are qualified in their entirety by reference to the full text of the Employment Agreement, the Option Agreement and the Kinnon SARs Agreement, which are filed herewith as Exhibit 10.1, Exhibit 10.2 and Exhibit 10.3, respectively, and are incorporated herein by reference.

 

For the period from February 20, 2013 through immediately prior to his appointment as Transgenomic’s Chief Executive Officer and President, Mr. Kinnon provided consulting services to Transgenomic pursuant to a Consulting Agreement, dated as of February 20, 2013, between Transgenomic and Mr. Kinnon, as amended (the “Consulting Agreement”). Pursuant to the Consulting Agreement, Mr. Kinnon received fees in the amount of $10,000-$20,000 per month. The Consulting Agreement will terminate, effective September 30, 2013, concurrent with Transgenomic’s appointment of Mr. Kinnon as its Chief Executive Officer and President pursuant to the Employment Agreement. Pursuant to the Consulting Agreement, Mr. Kinnon assisted Transgenomic in researching and developing commercial plans, supporting business development for Transgenomic’s technology, developing a market pricing strategy and negotiating certain commercial contracts.

 

On September 30, 2013, Transgenomic issued a press release announcing the appointment of Mr. Kinnon. A copy of the press release is filed herewith as Exhibit 99.1.

 

Grant of Stock Appreciation Rights to Mark P. Colonnese

 

Transgenomic approved the grant to Mark P. Colonnese, Transgenomic’s Executive Vice President and Chief Financial Officer, of SARs with respect to 660,000 shares of Transgenomic’s common stock with an exercise price equal to the fair market value of one share of Transgenomic’s common stock on the date of grant, which will be October 4, 2013. Thirty-four percent of the shares subject to the SARs will vest on the first anniversary of the date of grant, with the remaining shares subject to the SARs vesting ratably over the remaining 24 months, subject to Mr. Colonnese’s continued employment with Transgenomic on each such date. If Transgenomic terminates Mr. Colonnese’s employment without Just Cause (as defined in the Employment Agreement, dated September 12, 2012, by and between Transgenomic and Mr. Colonnese, as amended) prior to October 4, 2014, the SARs shall be deemed to have vested on a monthly basis at a rate of 1/36th per month from the grant date. The SARs will accelerate in full and become fully vested upon Mr. Colonnese’s death, disability or retirement if he has continuously served as a director, employee or advisor of Transgenomic for the two-year period immediately preceding such event. The SARs will be granted pursuant to the 2006 Equity Plan and a SARs agreement (the “Colonnese SARs Agreement”). Upon exercise of the SARs, Mr. Colonnese will be entitled to receive shares of Transgenomic common stock or cash, subject to the terms of the Colonnese SARs Agreement.

 

 
 

 

The foregoing description of the Colonnese SARs Agreement does not purport to be a complete description and is qualified in its entirety by reference to the full text of the Colonnese SARs Agreement, which is filed herewith as Exhibit 10.4 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

10.1Employment Agreement between Transgenomic and Paul Kinnon, effective September 30, 2013

 

10.2Form of Incentive Stock Option Agreement between Transgenomic and Paul Kinnon, effective October 4, 2013

 

10.3Form of Stock Appreciation Rights Agreement between Transgenomic and Paul Kinnon, effective October 4, 2013

 

10.4Form of Stock Appreciation Rights Agreement between Transgenomic and Mark Colonnese, effective October 4, 2013

 

10.5Form of Stock Appreciation Rights Agreement under the 2006 Equity Incentive Plan

 

99.1Press Release dated September 30, 2013, announcing the appointment of Paul Kinnon to the position of Chief Executive Officer and President

 

 
 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  TRANSGENOMIC, INC.
   
   
  By /s/ Rodney S. Markin, M.D., Ph.D.  
   

Rodney S. Markin, M.D., Ph.D.

Chairperson of the Board of Directors

   
   
September 30, 2013  

 

 

 
 

 

EX-10.1 2 v356113_ex10-1.htm EXHIBIT 10.1

 

EXHIBIT 10.1

 

 

EMPLOYMENT AGREEMENT

 

 

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of September 27, 2013, between Transgenomic, Inc., a Delaware corporation (“Employer”), and Paul Kinnon, an individual (“Executive”). This Agreement shall become effective as of September 30, 2013 (the “Effective Date”).

 

RECITAL

 

Employer desires to employ Executive, and Executive desires to be so employed by Employer, on the terms and subject to the conditions set forth in this Agreement.

 

AGREEMENT

 

NOW, THEREFORE, in consideration of the premises and the mutual promises set forth in this Agreement, Employer and Executive hereby agree as follows:

 

 

1. Term of Employment

(a) The term of Executive’s employment under this Agreement shall commence effective as of the Effective Date and end on the one-year anniversary of the Effective Date or such earlier date on which Executive’s employment is terminated under Section 9 of this Agreement (as may be modified hereunder, the “Expiration Date”); provided that, on the one-year anniversary and each subsequent anniversary of the Effective Date, the then-current term shall automatically be extended by successive one-year periods, unless Employer or Executive provides the other with written notice at least three months prior to the expiration of the then-current term that Employer or Executive wishes to terminate the Agreement, in which case the term shall not be extended. If the initial term or any subsequent extended term is extended, the Expiration Date shall be the last day of any such extended period, or such earlier date on which Executive’s employment is earlier terminated under Section 9 of this Agreement. The initial term and any extensions shall be referred to herein as the “Term.”

 

(b) Nothing in this Agreement shall impose upon Employer any obligation to retain Executive as an employee, and no such termination by Employer shall be deemed a breach of this Agreement. In addition, nothing in this Agreement shall restrict Executive from terminating his employment with Employer, and no such termination by Executive shall be deemed a breach of this Agreement.

 

(c) The provisions of Sections 8 and 10 of this Agreement, and this Section 1(c), shall survive the expiration or earlier termination of this Agreement.

 

2. Compensation

(a) In General. In full consideration for all rights and services provided by Executive under this Agreement, Executive shall receive the compensation set forth in this Section 2.

 

(b) Base Salary. Commencing on the Effective Date, Executive shall receive an annual base salary (as adjusted, “Base Salary”) of $350,000. Base Salary payments shall be made in accordance with Employer’s then prevailing payroll policy. Executive’s Base Salary shall be reviewed by the compensation committee of the Board of Directors of Employer (the “Compensation Committee”) for an increase on at least an annual basis and may be adjusted at any time if the Compensation Committee, in its sole and absolute discretion, elects to do so, but any Base Salary decreases must either be with Executive’s written permission, or be part of an across-the-board reduction that affects all senior executives of Employer by the same percentage. Executive will not earn any Base Salary during any period of time for which he is not performing active service for Employer, other than during permitted paid vacations and holidays pursuant to Section 7 of this Agreement, to the extent that similarly situated executive employees are not paid for such non-performance of services by Employer.

 

Page 1
 

(c) Annual Bonus. In addition to the Base Salary, starting January 1, 2014, Executive shall be eligible to receive an annual bonus based on his performance in conjunction with specific mutually agreed goals and objectives and formulas determined by the Compensation Committee in its sole discretion prior to, or within the first fiscal quarter of, each calendar year; provided that the target bonus for any year, starting January 1, 2014, shall not be less than 40% of Base Salary. Bonuses, if any, will be payable at such time or times during or following each calendar year as shall be determined by the Compensation Committee in its sole discretion.

 

(d) Equity Awards.

 

(i)Executive shall be entitled to the following equity awards, which awards shall be granted under and pursuant to the terms of Employer’s 2006 Equity Incentive Plan (the “Plan”) and the Employer’s standard forms of equity award agreements adopted by the Compensation Committee for use thereunder:

 

a. A stock option (the “Option”) to purchase 2,150,000 shares of common stock of Employer (the “Common Stock”), which Option shall be granted on the fifth (5th) business day immediately following the date of this Agreement (the “Grant Date”). One-third of the shares of Common Stock subject to the Option shall vest on the one-year anniversary of the Grant Date and the remaining shares shall vest in 24 substantially equal installments each month thereafter, subject to Executive’s continued employment with Employer on each such anniversary date; provided that if Employer terminates Executive’s employment without Cause (as defined below) or Executive terminates his employment for Good Reason (as defined below) prior to the one-year anniversary of the Grant Date, a total of one-third of the shares of Common Stock subject to the Option shall be deemed automatically vested. The Option shall be granted at an exercise price equal to the fair market value of one share of the Common Stock, as determined in accordance with the Plan (the “Exercise Price”).

 

Page 2
 

b. A stock appreciation right (the “SAR”) with respect to 1,000,000 shares of Common Stock, which SAR shall be granted on the Grant Date. The SAR shall vest at a rate of 34% on the one-year anniversary of the Grant Date, with ratable monthly vesting of the remaining amount over the remaining 24 months, in each case subject to Executive’s continued employment with Employer on each such anniversary date; provided that if Employer terminates Executive’s employment without Cause or Executive terminates his employment for Good Reason prior to the one-year anniversary of the Grant Date, a total of 34% of the SAR shall be deemed automatically vested. The SAR shall be granted at the Exercise Price and shall be settled in accordance with the terms of the stock appreciation rights agreement governing the SAR.

 

(ii)Notwithstanding anything herein to the contrary, the vesting of the Option, the SAR and any future equity award granted by Employer to Executive shall accelerate in full and become fully vested upon a Change in Control (as defined in the Plan).

 

(e) Clawback Provision. Notwithstanding any other provisions in this Agreement to the contrary, any incentive-based compensation, or any other compensation, paid to Executive pursuant to this Agreement or any other agreement or arrangement with Employer which is subject to recovery under any law, government regulation or stock exchange listing requirement, will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange listing requirement (or any policy adopted by Employer pursuant to any such law, government regulation or stock exchange listing requirement).

 

(f) Indemnification. Employer agrees to indemnify and hold Executive harmless to the degree, and subject to the conditions, set forth in Employer’s Certificate of Incorporation and Bylaws, and applicable Delaware law.

 

3. Title

Executive is being employed under this Agreement in the position of Chief Executive Officer, reporting directly to the Board of Directors of Employer (the “Board”) through its Chairman. As of the Effective Date or as soon thereafter as is reasonably practical, Executive will be appointed to the Board. For as long as Executive is serving as Employer’s Chief Executive Officer, Employer will nominate Executive for election to the Board; provided that Employer shall have no obligation to maintain Executive’s position on the Board, and Executive irrevocably appoints Employer and any of its executive officers to execute and deliver a resignation of such positions on Executive’s behalf at the end of the Term (or at the time Executive ceases to hold the position of Chief Executive Officer). Executive shall initially be based in Solana Beach, California, except for required travel on Employer’s business.

 

4. Duties

Executive shall have such duties and authority as may be assigned to him by the Board to the extent that such duties and authority are commensurate with Executive’s position. Executive shall personally and diligently perform, on a full-time and exclusive basis, such services as Employer or any of its related or affiliated entities or divisions may reasonably require. Executive will at all times perform all of the duties and obligations required by him under this Agreement in a loyal and conscientious manner and to the best of his ability and experience. Executive will be permitted to manage personal investments and to participate in civic, charitable, educational, and professional activities, to the extent that such activities do not compete with Employer or its affiliates and do not interfere with the performance of Executive’s job duties to Employer.

 

Page 3
 

5. Expenses

To the extent Executive incurs necessary, reasonable, actual and documented travel and business expenses in the course of his employment, Executive shall be reimbursed for such expenses, subject to Employer’s then-current policies regarding reimbursement of such travel and business expenses, but in any event such reimbursement shall be paid by March 15 of the year following the calendar year to which the expenses relate. Specifically, Employer will reimburse Executive for reasonable travel expenses associated with commuting on a weekly basis from Solana Beach, California to Omaha, Nebraska and New Haven, Connecticut. Reimbursable expenses include reasonable round-trip economy airfare, transportation to and from the airport, and hotel expenses, in amounts to be agreed upon between Executive and Employer.

 

6. Other Benefits

Executive shall be entitled to those benefits which are standard for senior executives of Employer, in each such case, subject to the terms and conditions of such plans, policies, and procedures. Executive expressly agrees and acknowledges that after the expiration of the Term, he is entitled to no additional benefits, except as specifically provided in this Agreement and except as specifically provided under the benefit plans referred to above and those benefit plans in which Executive subsequently may become a participant, and subject in each case to the terms and conditions of each such plan.

 

7. Vacation and Paid Holidays

Executive shall participate in the vacation benefit according to Employer’s vacation policy applicable to senior executives.

 

8. Protection of Employer’s Interests

(a) Duty of Loyalty. During the Term, Executive will owe a duty of loyalty to Employer, which includes, but is not limited to, not competing in any manner, whether directly or indirectly, as a principal, employee, agent, owner, or otherwise, with Employer, or any affiliate of Employer, except that the foregoing will not prevent Executive from passive investment in, at any time, less than four percent (4%) of the outstanding capital stock of any company whose stock is publicly traded.

 

(b) Policy Compliance. Executive confirms that he has read, understands, and will comply with Employer’s written policies, as amended or restated from time to time.

 

Page 4
 

(c) Property of Employer. All rights worldwide with respect to any and all intellectual or other property of any nature produced, created, or suggested by Executive during the Term or resulting from Executive’s services which (i) relate in any manner at the time of conception or reduction to practice to the actual or demonstrably anticipated business of Employer, (ii) result from, or are suggested by, any task assigned to Executive or any work performed by Executive on behalf of Employer, or (iii) are based on any property owned or idea conceived by Employer, shall be deemed to be a work made for hire, and shall be the sole and exclusive property of Employer. Executive agrees to execute, acknowledge, and deliver to Employer, at Employer’s request, such further documents, including copyright and patent assignments, as Employer finds appropriate to evidence Employer’s rights in such property. Executive’s agreement to assign to Employer any of Executive’s rights as set forth in this Section 8(c) shall not apply to any invention that qualifies fully under the provisions of California Labor Code Section 2870, where no equipment, supplies, facility, or trade secret information of Employer were used and such invention was developed entirely upon Executive’s own time, and such invention does not relate to Employer’s business, and such invention does not result from any work performed by Executive for Employer.

 

(d) Confidentiality. No confidential or proprietary information of Employer or any affiliate of Employer shall be used by Executive or disclosed or made available by Executive to any person except as required in the course of Executive’s employment, and upon the termination of Executive’s employment (or at any time on Employer’s request), Executive shall return to Employer all such information that exists, whether in electronic, written, or other form (and all copies thereof) under Executive’s control. Without limiting the generality of the foregoing, Executive acknowledges signing and delivering to Employer the Employee Confidentiality Agreement as of the Effective Date (the “Confidentiality Agreement”) and Executive agrees that all terms and conditions contained in such agreement, and all of Executive’s obligations and commitments provided for in such agreement, shall be deemed, and hereby are, incorporated into this Agreement as if set forth in full herein. Executive also acknowledges that upon termination of his employment for any reason whatsoever (or at any time on Employer’s request), he will promptly deliver to Employer, or surrender to Employer’s representative, all property of Employer and its affiliates, including without limitation, all documents and other materials (and all copies thereof) relating to Employer’s and its affiliate’s business, all identification and access cards, all contact lists and third party business cards however and wherever preserved, and any equipment provided by Employer or its affiliates, including computers, telephones, personal digital assistants, memory cards, and similar devices which Executive possesses or has in his custody or under his control.

 

(e) Covenant Not to Compete or Solicit. During the Term, Executive shall not, either alone or jointly, with or on behalf of others, directly or indirectly, whether as principal, partner, agent, shareholder, director, employee, consultant or otherwise: (a) offer employment to, or directly or indirectly solicit the employment or engagement of, or otherwise entice away from the employment of Employer or any affiliated entity, either for Executive’s own account or for any other person, firm or company, any person who was employed by Employer or any of its affiliates during the Term, whether or not such person would commit any breach of a contract by reason of his or her leaving the service of Employer or its affiliates; (b) directly or indirectly solicit, induce or entice any client, customer, contractor, licensor, agent, partner or other business relationship of Employer or its affiliates to terminate, discontinue, renegotiate or otherwise cease or modify its relationship with Employer or its affiliates; or (c) engage in any competitive activity with Employer. For a period of (i) six months following Executive’s termination of employment by Employer without Cause or by Executive for Good Reason, and (ii) one year following Executive’s termination of employment for any other reason whatsoever, Executive shall not, either alone or jointly, with or on behalf of others, directly or indirectly, whether as principal, partner, agent, shareholder, director, employee, consultant or otherwise offer employment to, or directly or indirectly solicit the employment or engagement of, or otherwise entice away from the employment of Employer or its affiliates, either for Executive’s account or for any other person, firm or company, any person who was employed by Employer or its affiliates within the then preceding six months, whether or not such person would commit any breach of a contract by reason of his or her leaving the service of Employer or its affiliates. Executive expressly acknowledges and agrees that the restrictions contained in this Section 8(e) are reasonably tailored to protect Employer’s and its affiliate’s confidential information and trade secrets, and are reasonable in all circumstances in scope, duration and all other respects. It is expressly agreed by the parties that if for any reason whatsoever, any one or more of such restrictions shall (either taken by itself or themselves together) be adjudged to go beyond what is legally permissible for the protection of the legitimate interests of Employer and its affiliates, that the prohibitions shall be in effect and upheld to the fullest extent permissible under applicable laws.

 

Page 5
 

(f) No Disparagement. Executive agrees and represents that he will not defame or disparage Employer either orally or in writing. Employer agrees and represents that it will instruct its employees not to defame or disparage Executive either orally or in writing. Executive further agrees to refrain from directly or indirectly engaging in publicity, including written, oral and electronic communication of any kind, or any other activity which reflects negatively or adversely upon Employer, its business, its actions or its officers, directors or employees, whether or not Executive believes the content of the publicity to be true or whether or not it is, in fact, true. The restrictions in this Section 8(f) do not apply to truthful testimony compelled by applicable law or legal process or to truthful information that either party or their representatives provides to any governmental agency.

 

9. Termination

(a) Right to Terminate; Accrued Benefits. Executive is an employee at-will, and Executive’s employment may be terminated at any time and for any reason, or for no reason, by either Executive or Employer. In all cases of termination (including expiration of the Term), except as expressly set forth in the remainder of this Section 9, Employer shall be obligated only to provide Executive with (1) the earned but unpaid Base Salary through the date of Executive’s termination; (2) any accrued but unused vacation time; (3) any benefits not including the Severance Benefits, as defined in Section 9(f) of this Agreement, which have accrued to Executive prior to termination; (4) reimbursement of approved expenses due to Executive pursuant to Section 5 of this Agreement; and (5) if Executive’s employment is terminated after completion of a calendar year on account of death under Section 9(e) of this Agreement, or is terminated by Employer on account of Disability pursuant to Section 9(d) of this Agreement or without Cause pursuant to Section 9(f) of this Agreement, or is terminated by Executive for Good Reason pursuant to Section 9(f) of this Agreement, (A) any Annual Bonus for the prior calendar year earned but not yet paid; and (B) an Annual Bonus for the year in which Executive’s termination of employment occurs, which shall be payable solely if and when annual bonuses are paid to other employees of Employer, prorated from the commencement of such year through the effective date of the termination of Executive’s employment (collectively, the “Accrued Benefits”).

 

Page 6
 

(b) Resignation. At any time during the Term, Executive may resign upon not less than thirty (30) days prior written notice to Employer. Upon receipt of Executive’s notice of resignation, Employer may terminate Executive’s employment prior to the date stated in such notice and such termination will be treated as a resignation by Executive for all purposes of this Agreement. In the event of Executive’s resignation, or termination by Employer following receipt of Executive’s notice of resignation, Executive will receive only the Accrued Benefits.

 

(c) By Employer for Cause. At any time during the Term, Employer may terminate Executive’s employment and this Agreement for “Cause,” which shall mean that Executive (i) engaged in willful, reckless or gross misconduct, (ii) materially breached this Agreement or any other agreement between him and Employer, (iii) committed, was convicted of, or pled no contest to a felony or crime involving dishonesty or moral turpitude, (iv) breached his duty of loyalty, (v) willfully or negligently violated Employer’s material policies, or (vi) willfully or negligently failed to follow any lawful written directive of Employer that is not inconsistent with this Agreement; provided that, with respect to Executive’s negligent violation under clause (v) above and negligent failure under clause (vi) above , Executive shall have 20 days to cure such violation or failure if Employer’s Board of Directors determines that such violation or failure is capable of being cured. If Executive’s employment ends for any reason other than termination by Employer for Cause, at a time when Employer had Cause to terminate Executive (or would have had Cause if it then knew all relevant facts), Executive’s termination shall be treated as a discharge by Employer for Cause. If Executive’s employment is terminated for Cause, Employer shall be obligated to provide Executive only with the Accrued Benefits.

 

(d) By Employer for Disability. At any time during the Term, Employer may terminate Executive’s employment and this Agreement on account of Executive’s Disability, except as prohibited by applicable law. “Disability” shall mean that Executive is unable to perform any of the essential duties of his position by reason of any medically determinable physical or mental impairment. If Executive’s employment is terminated for Disability, Employer shall be obligated to provide Executive only with the Accrued Benefits.

 

(e) Termination on Death. In the event of Executive’s death during the Term, this Agreement and Executive’s employment shall terminate as of the date of Executive’s death, and Employer shall be obligated to provide Executive’s heirs, successors, legal representatives, or estate only the Accrued Benefits. Nothing in this Agreement shall limit any payments Executive’s widow, beneficiaries, or estate may be entitled to receive pursuant to any pension or employee benefit plan or life insurance policy maintained by Employer.

 

Page 7
 

(f) By Employer without Cause (Other Than on Account of Disability); By Executive for Good Reason. Employer may terminate Executive’s employment and this Agreement at any time without Cause, and such termination shall not be deemed a breach by Employer of any term of this Agreement or any other duty or obligation, expressed or implied, which Employer may owe to Executive pursuant to any principle or provision of law. Subject to the remaining terms of this Section 9(f), Executive may terminate his employment and this Agreement at any time for Good Reason, and such termination shall not be deemed a breach by Executive of any term of this Agreement or any other duty or obligation, expressed or implied, which Executive may owe to Employer pursuant to any principle or provision of law. In the event of termination by Employer other than for Cause, or by Executive for Good Reason, in either case during the Term, this Agreement and Executive’s employment shall terminate as of the date specified in the termination notice (subject to the limitations provided in this section 9(f)), and Employer shall be obligated to provide Executive with only the Accrued Benefits and “Severance Benefits,” defined as 12 months of Executive’s then-current Base Salary in the form of salary continuation payable according to Employer’s then-current payroll schedule, commencing on the next payroll date following the 65th day of such a termination and each payment of which shall be considered a separate “payment” for purposes of Section 409A of the Internal Revenue Code and the regulations thereunder (“Section 409A”). Notwithstanding the foregoing, no portion of the Severance Benefits shall be payable unless, within 65 days following Executive’s termination of employment, Executive signs a severance agreement and general release in substantially the form attached hereto as Exhibit A, with such changes therein or additions thereto as needed under then applicable law to give effect to its intent and purposes and ensure its enforceability. For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following events without the express written consent of the Executive, provided that (i) Executive gives Employer written notice of such event within 30 days of the initial existence of such event, (ii) such event is not corrected in all material respects by Employer within 90 days following written notification by Executive to Employer of the occurrence of such event, and (iii) Executive terminates his employment with Employer within five days following such 90-day remedy period: Employer (W) assigns to Executive duties (including titles and reporting relationships) inconsistent in any material respect with the Executive’s duties or responsibilities as contemplated by this Agreement; (X) materially breaches this Agreement or any other agreement between Employer and Executive; (Y) requires Executive to relocate to any jurisdiction other than Omaha, Nebraska (or Employer’s principal place of business, if other than Omaha, Nebraska); or (Z) requires that Executive’s one-way commute increase by more than 50 miles from Solana Beach, California.

 

(g) Termination of Obligations and Severance Payments. In the event of termination of Executive’s employment and this Agreement, all obligations of Employer to Executive under this Agreement shall immediately terminate except as provided in this Section 9 and Sections 2(e), 10(k), and 10(t).

 

(h) Breach of Post-Termination Obligations. In the event that Executive breaches any of his obligations under Section 8 of this Agreement, Employer may suspend payment of any Severance Benefits, to the extent not prohibited by law; provided, however, that if it is subsequently determined by a court of competent jurisdiction or binding arbitration that Executive did not breach such obligation (for the sake of clarity, this provision does not create an independent right to seek such a determination from a court), all suspended Severance Benefits shall be immediately paid to Executive.

 

Page 8
 

10. General Provisions

(a) Entire Agreement. This Agreement, together with the Confidentiality Agreement, supersedes all prior or contemporaneous agreements and statements, whether written or oral, concerning the terms of Executive’s employment with Employer, and no amendment or modification of these agreements shall be binding unless it is set forth in a writing signed by both Employer and Executive. To the extent that this Agreement conflicts with any of Employer’s policies, procedures, rules, or regulations, this Agreement shall supersede the other policies, procedures, rules, or regulations. Employer and Executive specifically agree that this Agreement supersedes any and all agreements or arrangements between Employer and Executive, including, but not limited to, that certain Consulting Agreement between Employer and Executive, dated February 20, 2013, as amended (the “Consulting Agreement”); provided, however, that nothing in this Agreement shall diminish Executive’s right to any payments owed to him under Sections 4(a) or 4(b) of the Consulting Agreement, with respect to time periods ending prior to the Effective Date. Notwithstanding anything herein to the contrary, the stock option grant to purchase 150,000 shares of Common Stock contemplated under the Consulting Agreement shall be deemed rescinded by the Company, terminated and of no further force or effect. For the avoidance of doubt, Employer and Executive hereby agree that any notification requirement with respect to the termination of the Consulting Agreement has been satisfied.

 

(b) Assignment. Employer may assign this Agreement, or all or any part of its rights under this Agreement, to any entity which succeeds to all or substantially all of Employer’s stock or assets (whether by merger, acquisition, consolidation, reorganization, or otherwise), which entity expressly assumes and agrees to be bound by this Agreement, after which Transgenomic, Inc. shall have no remaining liability under this Agreement and all references to Employer shall instead be deemed to refer to such assignee, and this Agreement shall inure to the benefit of such assignee. Employer may also assign this Agreement to a subsidiary, but such assignment shall have no effect upon Executive’s rights or Employer’s liability to Executive hereunder in the event that such subsidiary breaches the terms of this Agreement.

 

(c) No Conflict with Prior Agreements; Covenant. Executive represents to Employer that neither Executive’s commencement of employment under this Agreement nor the performance of Executive’s duties under this Agreement conflicts or will conflict with any contractual or legal commitment on Executive’s part to any third party, nor does it or will it violate or interfere with any rights of any third party. Executive covenants to Employer that Executive will not enter into any agreement that conflicts with any contractual or legal commitment of Executive to the Employer pursuant to this Agreement.

 

(d) Successors.

 

(i)This Agreement is personal to Executive and without the prior written consent of Employer shall not be assignable by Executive. This Agreement shall inure to the benefit of and be enforceable by Executive’s legal representatives.

 

(ii)Subject to Section 10(b) of this Agreement, this Agreement shall inure to the benefit of and be binding upon Employer and its successors and assigns, including any successor by reason of merger, sale of all or substantially all of the assets of Employer, or by operation of law.

 

Page 9
 

 

(e) No Broker. Executive has given no indication, representation, or commitment of any nature to any broker, finder, agent, or other third party to the effect that any fees or commissions of any nature are, or under any circumstances might be, payable by Employer or any of its affiliates in connection with Executive’s employment under this Agreement.

 

(f) Waiver. No waiver by either party of any breach by the other party of any provision or condition of this Agreement shall be deemed a waiver of any similar or dissimilar provision or condition at the same or any prior or subsequent time.

 

(g) Prevailing Law. Nothing contained in this Agreement shall be construed so as to require the commission of any act contrary to law, and wherever there is any conflict between any provision of this Agreement and any present or future statute, law, ordinance or regulation, the latter shall prevail; but in such event, the provision of this Agreement affected shall be curtailed and limited only to the extent necessary to bring it within legal requirements.

 

(h) Expiration. This Agreement does not constitute a commitment of Executive or Employer with regard to Executive’s employment, express or implied, other than to the extent expressly provided for herein. Upon expiration of the term of this Agreement, it is the contemplation of both parties that Executive’s employment with Employer shall cease, and that neither Employer nor Executive shall have any obligation to the other with respect to Executive’s continued employment, except as otherwise expressly provided in this Agreement.

 

(i) Choice of Law. The corporate law of the State of Delaware will govern all questions concerning the relative rights of Employer and its stockholders. All other questions concerning the construction, validity, and interpretation of this Agreement shall be governed by the internal laws of the State of Nebraska.

 

(j) Immigration. In accordance with the Immigration Reform and Control Act of 1986, employment under this Agreement is conditioned upon satisfactory proof of Executive’s identity and legal ability to work in the United States.

 

(k) Arbitration. All disputes relating to Executive’s employment (or its termination), including disputes relating to this Section and this Agreement, shall be resolved by final and binding arbitration in accordance with this Section. The arbitration will be conducted by an impartial arbitrator experienced in employment law and who is either a retired judge or who is currently licensed to practice law, selected from the JAMS panel of arbitrators in accordance with JAMS then current employment arbitration rules (except as otherwise provided in this Section). Executive understands that Employer and Executive are waiving the right to institute a court action, except for requests for injunctive relief pending arbitration, and understands that Employer and Executive are giving up any right to a jury trial. The arbitrator’s award and opinion shall be in writing and in the form typically rendered in labor and employment arbitrations.

 

Prior to a final arbitral decision, Executive and Employer shall each pay one-half of the costs and expenses of such arbitration and each shall separately pay the fees and expenses of their respective legal counsel. Ultimately, the arbitrator shall award attorneys’ fees and costs to the prevailing party, unless prohibited by applicable law. This arbitration obligation shall not prohibit Employer or Executive from filing a claim with an administrative agency (e.g., the EEOC), nor does it apply to claims for Workers’ Compensation or unemployment benefits, or claims for benefits under an employee welfare or pension plan that specifies a different dispute resolution procedure. The arbitration shall take place in Omaha, Nebraska, unless Employer and Executive agree otherwise.

 

Page 10
 

(l) Severability. If any provision of this Agreement is held to be illegal, invalid, or unenforceable under existing or future laws effective during the Term, such provisions shall be fully severable, the Agreement shall be construed and enforced as if such illegal, invalid, or unenforceable provision had never comprised a part of this Agreement, and the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid, or unenforceable provision or by its severance from this Agreement. Furthermore, in lieu of such illegal, invalid, or unenforceable provision, there shall be added automatically as part of this Agreement a provision as similar in terms to such illegal, invalid, or unenforceable provision as may be possible and be legal and enforceable.

 

(m) Legal Counsel. Executive acknowledges that he has been given the opportunity to consult with legal counsel or any other advisor of his own choosing regarding this Agreement. Executive understands and agrees that Employer’s in-house attorneys, or any other attorney retained by Employer, or any member of management who has discussed any term or condition of this Agreement with him or with Executive, is only acting on behalf of Employer and not on Executive’s behalf.

 

(n) Right to Negotiate. Executive hereby acknowledges that he has been given the opportunity to participate in the negotiation of the terms of this Agreement. Executive acknowledges and confirms that he has read this Agreement and fully understands its terms and contents.

 

(o) Injunctive Relief. In the event of a breach of, or threatened breach of, the provisions of this Agreement regarding the exclusivity of Executive’s services and the provisions of Sections 8 and 10 of this Agreement, Executive agrees that any remedy of law would be inadequate. Accordingly, Executive agrees that Employer is entitled to seek injunctive relief for such breaches or threatened breaches. The injunctive relief provided for in this Section 10(o) is in addition to, and is not in limitation of, any and all other remedies at law or in equity otherwise available to the applicable party. The parties agree to waive the requirement of posting a bond or other security in connection with a court or arbitrator’s issuance of an injunction.

 

(p) Remedies Cumulative. The remedies in this Agreement are not exclusive, and the parties shall have the right to pursue any other legal or equitable remedies to enforce the terms of this Agreement.

 

(q) Headings. The headings set forth herein are included solely for the purpose of identification and shall not be used for the purpose of construing the meaning of the provisions of this Agreement.

Page 11
 

 

(r) Section 409A. If any amounts that become due under Section 9 of this Agreement constitute “nonqualified deferred compensation” within the meaning of Section 409A, payment of such amounts shall not commence until Executive incurs a “separation from service” within the meaning of Treasury Regulation Section 1.409A-1(h). If, at the time of Executive’s separation from service, Executive is a “specified employee” (under Internal Revenue Code Section 409A), any benefits as to which Section 409A penalties could be assessed that become payable to Executive on account of his “separation from service” (including any amounts payable pursuant to the preceding sentence) will not be paid until after six months and one day after Executive’s separation from service (the “409A Suspension Period”). Within 14 calendar days after the end of the 409A Suspension Period, Executive shall be paid a lump sum payment in cash equal to any payments delayed because of the preceding sentence, together with interest on them for the period of delay at a rate not less than the average prime interest rate published in the Wall Street Journal on any day chosen by Employer during that period. Thereafter, Executive shall receive any remaining benefits as if there had not been an earlier delay.

 

(s) Section 280G. In the event that any payment or benefit received or to be received by Executive pursuant to this Agreement or under any other agreement, contract, award, arrangement, etc. (collectively, “Payments”) would result in a “parachute payment” as described in Section 280G of the Internal Revenue Code of 1986, as amended (or any successor provision), notwithstanding the other provisions of this Agreement, or any other agreement, contract, award, arrangement, etc., such Payments shall not, in the aggregate, exceed the maximum amount that may be paid to Executive without triggering golden parachute penalties under Section 280G and related provisions of the Internal Revenue Code, as determined in good faith by Employer’s independent auditors. If any benefits must be cut back to avoid triggering such penalties, they shall be cut back in the following order:  First a pro rata reduction of (i) cash payments subject to Section 409A of the Code as deferred compensation and (ii) cash payments not subject to Section 409A of the Code, and second a pro rata cancellation of (i) equity-based compensation subject to Section 409A of the Code as deferred compensation and (ii) equity-based compensation not subject to Section 409A of the Code.  Reduction in either cash payments or equity compensation benefits shall be made pro rata between and among benefits which are subject to Section 409A of the Code and benefits which are exempt from Section 409A of the Code.  If an amount in excess of the limit set forth in this Section 10(s) is paid to Executive, Executive shall repay the excess amount to Employer on demand, with interest at the rate provided for in Internal Revenue Code Section 1274(b)(2)(B) (or any successor provision). Employer and Executive agree to cooperate with each other in connection with any administrative or judicial proceedings concerning the existence or amount of golden parachute penalties. The foregoing reduction, however, shall only apply if it increases the net amount Executive would realize from Payments, after payment of income and excise taxes on such Payments.

 

(t) Survivability. The provisions of this Agreement shall survive the termination or expiration of this Agreement and of Executive’s employment for any reason, to the extent required to enable the parties to enforce their respective rights hereunder.

 

Page 12
 

(u) Deductions from Salary, Bonus and Benefits. Employer may withhold from any Base Salary, Annual Bonus, equity or other benefits payable to Executive all federal, state, local, and other taxes and other amounts as permitted or required pursuant to law, rule, or regulation.

 

11. Notices

All notices which either party is required or may desire to give the other shall be in writing and given either personally or by depositing the same in the United States mail addressed to the party to be given notice as follows: 

 

 To Employer: Transgenomic, Inc.
12325 Emmet Street
Omaha, NE 68164
Attention: Chairman of the Board
Telephone: (402) 452-5400
Telecopy: (402) 452-5447

 

 

 To Executive:

Paul Kinnon

___________________________

___________________________

 

Either party may, by written notice, designate a different address for giving of notices. The date of mailing of any such notices shall be deemed to be the date on which such notice is given. 

 

 

ACCEPTED AND AGREED TO:

 

 

Employer   Executive
Transgenomic, Inc.    
By: /s/ Rodney S. Markin, M.D., Ph.D.   /s/ Paul Kinnon
  Rodney S. Markin, M.D., Ph.D.   Paul Kinnon
     


Page 13
 

 

Exhibit A

 

Form of Severance Agreement and General Release

 

 

 

 

 

 

 

Page 14

EX-10.2 3 v356113_ex10-2.htm EXHIBIT 10.2

EXHIBIT 10.2

 

 

 

Description: header2

 

TRANSGENOMIC, INC. 2006 EQUITY INCENTIVE PLAN

 

INCENTIVE STOCK OPTION AGREEMENT

 

THIS STOCK OPTION AGREEMENT (this “Agreement”) is effective October 4, 2013 (the “Grant Date”) by and between Transgenomic, Inc., a Delaware corporation (the “Company”) and Paul Kinnon (“Grantee”).

 

WHEREAS, the Company sponsors and maintains the Transgenomic, Inc. 2006 Equity Incentive Plan (the “Plan”); and

 

WHEREAS, Grantee, as an Eligible Person, has been selected to receive a grant of Incentive Stock Options under the Plan.

 

NOW, THEREFORE, the Company and Grantee hereby agree as follows:

 

Section 1. General. This Agreement and the Incentive Stock Options granted hereunder are subject in all respects to the terms and conditions of the Plan. Capitalized terms used in this Agreement without further definition shall have the same meanings given to such terms in the Plan.

 

Section 2. Grant of Options. The Company hereby awards to Grantee, as of the Grant Date, Incentive Stock Options (the “Options”) equating to 2,150,000 shares of the Company’s common stock, $0.01 par value (the “Common Stock”). The Options have an exercise price of $[●] per share (the “Exercise Price”), which is no less than 100% of the Fair Market Value of a share of Common Stock on the Grant Date.

 

Section 3. Vesting & Duration. Options may not be exercised until they are vested, and shall vest as follows: 716,666 Options shall vest on the one-year anniversary of the Grant Date, with 59,722 Options vesting per month over the next 23 months and 59,728 Options vesting on the three-year anniversary of the Grant Date, in each case provided that Grantee remains continuously employed with (or is providing continued service to) the Company through the applicable vesting date, inclusive; and provided further that if the Company terminates Grantee’s employment without Cause, or if Grantee terminates his employment with the Company for Good Reason (each as defined under that certain Employment Agreement, effective October 1, 2013, by and between the Company and Grantee (as may be amended or restated from time to time)) prior to the one-year anniversary of the Grant Date, a total of 716,666 Options shall be deemed automatically vested.

 

These Options shall be exercised during such term only in accordance with the terms of the Plan.

 

Notwithstanding the foregoing, Grantee’s Options will become 100% vested in the event of Grantee’s Termination of Service as a result of Grantee’s Disability, death or Retirement, provided that Grantee has continuously served as a director, employee or Advisor of the Company for the two-year period immediately preceding Grantee’s Termination of Service. Any fraction of a share that becomes exercisable on any date will be rounded down to the next lowest whole number and any fraction of a share shall be added to the portion of the Option becoming exercisable on the following vesting date.

 

1
 

 

 

Section 4. Term of Options. The Options hereunder will expire ten years following the Grant Date. Notwithstanding the foregoing, Options will terminate earlier as provided below.

 

(a) Termination of Service. Upon Grantee’s Termination of Service by the election of the Company for any reason other than Grantee’s death, Retirement or Disability (other than for Cause), Grantee may exercise an Option at any time within ninety days from Grantee’s Termination of Service, but only to the extent that, as of the date of Grantee’s Termination of Service, Grantee’s right to exercise the Options has vested and Grantee has not previously exercised the Options. Any Option unexercised following such period shall be forfeited as of the expiration date of such period. Notwithstanding the foregoing, if Grantee suffers a Termination of Service for Cause or the Termination of Service occurs by the election of Grantee (other than an election because of death, Disability or Retirement), Grantee’s unexercised Options as of the date of his or her Termination of Service shall be cancelled and forfeited as of such date.

 

(b) Death, Retirement or Disability. Upon Grantee’s Termination of Service by reason of Grantee’s death, Retirement or Disability, or if Grantee dies with exercise rights under Section 4(a) above, Grantee (or his or her beneficiary in the case of death) may exercise the Options at any time within 12 months from Grantee’s Termination of Service, but only to the extent that, at the date of Termination of Service, Grantee’s right to exercise the Options has vested and Grantee has not previously exercised the Options. Any Options unexercised following such period shall be forfeited as of the expiration date of such period.

 

Section 5. Exercise of Stock Options. Subject to the provisions hereof, including Section 3, this Option may be exercised in whole or in part at any time, within the period permitted for the exercise thereof, with respect to whole shares only. To exercise this Option, Grantee or the Successor of the Participant must give written notice of intent to exercise this Option with respect to a specified number of shares delivered to the Company at its principal office and payment in full to the Company at said office of the amount of the Exercise Price for the number of shares with respect to which this Option is being exercised. The Company will determine the amount of any applicable taxes which require withholding as a result of the exercise, and Grantee must provide for such taxes as required by Section 10 hereof and the Plan.

 

Section 6. Payment. Payment of the Exercise Price shall be in cash; provided, however, the Compensation Committee, in its sole and absolute discretion, may permit Grantee to pay for shares to be acquired by exercise under an Option in any combination of cash and the transfer and delivery to the Company of stock of the Company having a Fair Market Value on the date of exercise of the Option at least equal to the Exercise Price. Grantee shall also pay the amount of any Federal, state or local taxes required to be withheld at the time of issuance of Common Stock hereunder. If no such taxes are required to be withheld at the time of such issuance, Grantee hereby agrees to pay to the Company the amount of such taxes, if any, thereafter required to be withheld by the Company.

 

2
 

Section 7. Issuance of Shares. Following exercise of any portion of this Option, payment of any applicable taxes and satisfaction of any other terms and conditions of this Agreement or the Plan, the Company will issue the number of shares of Common Stock purchased under this Option. Grantee or the Successor of the Participant has no right or any privilege of a shareholder of the Company in respect of any shares issuable on the exercise of this Option unless and until such shares have been recorded on the Company’s official shareholder records as having been issued and transferred.

 

Section 8. Special Rules of Incentive Stock Options. A grant of an Option hereunder shall be treated as an incentive stock option pursuant to Section 422 of the Internal Revenue Code. Grantee acknowledges that the tax treatment of shares subject to an incentive stock option or any events or transaction with respect thereto may be dependent upon various factors or events which are not determined by the Plan or this Agreement. For example, shares acquired by Grantee by exercise of this Option within two years from the date of this Agreement or one year from the date such Incentive Stock Option is exercised shall result in disqualification of incentive stock option tax treatment. If an Incentive Stock Option fails to meet the requirements of Section 422 of the Code, it shall automatically be redesignated as a Nonqualified Stock Option for federal income tax purposes. The Company makes no representations with respect to and hereby disclaims all responsibility as to such tax treatment. Grantee should consult his or her own tax advisor as to the tax treatment of an Incentive Stock Option.

 

Grantee further acknowledges that an Incentive Stock Option will be deemed to be a Nonqualified Stock Option to the extent required by the $100,000 annual limitation under Internal Revenue Code Section 422(d) and Section 7.4(a) of the Plan.

 

Section 9. Nontransferability of Options. Except as the Company and Grantee may agree in accordance with Section 6.3 of the Plan, the Options may not be sold, pledged, assigned, hypothecated, transferred or disposed of by Grantee in any manner other than by will or the laws of descent and distribution. No transfer of an Option by will or the laws of descent and distribution shall be effective to bind the Company unless the Company is furnished with written notice thereof and appropriate documentation evidencing the rights of any successor(s) of the Participant as the Compensation Committee deems necessary or desirable.

 

Section 10. Tax Treatment. By executing this Agreement, Grantee authorizes the Company to withhold, or Grantee agrees to pay to the Company, the full amount of all Federal, state and local taxes (including, but not limited to income, employment, FICA and/or Medicare taxes) applicable to any taxable income resulting from the exercise of rights pursuant to this Agreement and as permitted by Section 12.8 of the Plan.

 

Grantee acknowledges and accepts that exercise of Options hereunder may result in application of the Alternate Minimum Tax and that estate and/or other taxes may apply with respect to Options hereunder in the event of Grantee’s death. Grantee understands that he or she should seek his or her own tax advice regarding this Option and any rights hereunder.

 

3
 

Section 11. Miscellaneous Provisions.

 

(a) No Retention Rights. Nothing in this Agreement shall confer upon Grantee any right to continue in the employment or service of the Company for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company or of Grantee, which rights are hereby expressly reserved by each, to terminate his or her employment or service at any time and for any reason, with or without cause.

 

(b) Antidilution. In the event that any change in the outstanding shares of Common Stock of the Company (including an exchange of Common Stock for stock or other securities of another corporation) occurs by reason of a Common Stock dividend or split, recapitalization, merger, consolidation, combination, exchange of shares or other similar corporate changes, other than for consideration received by the Company therefore, the number of shares of stock granted hereunder or the Exercise Price may be appropriately adjusted by the Compensation Committee in its sole and absolute discretion, whose determination shall be conclusive, final and binding; provided, however that fractional shares shall be rounded to the nearest whole share. In the event of any other change in the Common Stock, the Compensation Committee shall in its sole discretion determine whether such change equitably requires a change in the number or type of shares of stock granted hereunder or the Exercise Price and any adjustment made by the Compensation Committee shall be conclusive, final and binding.

 

(c) Determination of Value. The Company makes no representation as to the value of this Option or whether Grantee will be able to realize any profit from it.

 

(d) Plan. The provisions of the Plan are incorporated by reference into these terms and conditions. To the extent any provision of this Agreement conflicts with the Plan, the terms of the Plan shall govern. Grantee acknowledges receipt of a copy of the Plan and represents that he or she has reviewed the Plan and is familiar with the terms and provisions thereof. Grantee hereby accepts this Agreement and the terms of the Plan.

 

(e) Notices. Any notice required by the terms of this Agreement shall be given in writing and shall be deemed effective upon personal delivery, upon deposit with the United States Postal Service, by registered or certified mail, with postage and fees prepaid or upon deposit with a reputable overnight courier. Notice shall be addressed to the Company at its principal executive office and to Grantee at the address most recently provided by Grantee to the Company.

 

(f) Blackout Periods. In connection with certain corporate events, the Company reserves the right to designate periods during which Grantee may not exercise this Option.

 

(g) Entire Agreement; Amendments. This Agreement constitutes the entire contract between the parties hereto with regard to the subject matter hereof. This Agreement supersedes any other agreements, representations or understandings (whether oral or written and whether express or implied) which relate to the subject matter hereof. The Compensation Committee shall have authority, subject to the express provisions of the Plan, to interpret this Agreement and the Plan, to establish, amend and rescind any rules and regulations relating to the Plan, to modify the terms and provisions of this Agreement, and to make all other determinations in the judgment of the Compensation Committee necessary or desirable for the administration of the Plan. The Compensation Committee may correct any defect or supply any omission or reconcile any inconsistency in the Plan or in this Agreement in the manner and to the extent it shall deem necessary or desirable to carry it into effect. All action by the Compensation Committee under the provisions of this paragraph shall be final, conclusive and binding for all purposes.

 

4
 

(h) Change in Control. Unless provided otherwise in connection with the transaction resulting in the Change in Control, immediately preceding the occurrence of a Change in Control of the Company, Unvested Stock Options shall immediately vest in full and to the extent not expired or previously exercised become immediately exercisable.

 

(i) Choice of Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, as such laws are applied to contracts entered into and performed in such State, without giving effect to the choice of law provisions thereof.

 

(j) Successors. This Agreement is personal to Grantee and, except as otherwise provided above, shall not be assignable by Grantee otherwise than by will or the laws of descent and distribution, without the written consent of the Company. This Agreement shall inure to the benefit of and be enforceable by Grantee’s legal representatives. This Agreement shall inure to the benefit of and be binding upon the Company and its successors. It shall not be assignable by the Company except in connection with the sale or other disposition of all or substantially all the assets or business of the Company.

 

(k) Severability. If any provision of this Agreement for any reason should be found by any court of competent jurisdiction to be invalid, illegal or unenforceable, in whole or in part, such declaration shall not affect the validity, legality or enforceability of any remaining provision or portion hereof, which remaining provision or portion hereof shall remain in full force and effect as if this Agreement had been adopted with the invalid, illegal or unenforceable provision or portion hereof eliminated.

 

(l) Headings. The headings and captions in this Agreement shall not be construed to limit or modify the terms or meaning of this Agreement.

 

 

5
 

  

This Agreement is executed by the Company and Grantee as of the date and year first written above.

 

Transgenomic, INC.
 
 
By:  
Name: Rodney S. Markin, M.D., Ph.D.
Title: Chairman of the Board of Directors
 
GRANTEE
 
 
 

Paul Kinnon

     
 
   

 

6

 

 

EX-10.3 4 v356113_ex10-3.htm EXHIBIT 10.3

EXHIBIT 10.3

 

 

 

Description: header2

 

TRANSGENOMIC, INC. 2006 EQUITY INCENTIVE PLAN

 

STOCK APPRECIATION RIGHTS AGREEMENT

 

 

THIS STOCK APPRECIATION RIGHTS AGREEMENT (this “Agreement”) is effective October 4, 2013 (the “Grant Date”) by and between Transgenomic, Inc., a Delaware corporation (the “Company”) and Paul Kinnon (“Grantee”).

 

WHEREAS, the Company sponsors and maintains the Transgenomic, Inc. 2006 Equity Incentive Plan, a copy of which is attached hereto as Exhibit A (the “Plan”); and

 

WHEREAS, Grantee, as an Eligible Person, has been selected to receive a grant of Stock Appreciation Rights under the Plan.

 

NOW, THEREFORE, the Company and Grantee hereby agree as follows:

 

Section 1. General. This Agreement and the Stock Appreciation Rights granted hereunder are subject in all respects to the terms and conditions of the Plan. Capitalized terms used in this Agreement without further definition shall have the same meanings given to such terms in the Plan. The award of Stock Appreciation Rights of the Company described herein (this “Award”) is conditioned on Grantee’s execution of the Award within ten (10) days after the Grant Date.

 

Section 2. Grant of Stock Appreciation Rights. The Company hereby awards to Grantee, as of the Grant Date, Stock Appreciation Rights with the following terms:

 

Grant Date October 4, 2013
Vesting Commencement Date October 4, 2013
Number of Shares measuring the value of the Award 1,000,000 Shares (the “SAR Shares”)
Exercise Price per SAR Share $[_____._____] per Share (the “Exercise Price”)

 

 
 

 

Vesting Schedule

340,000 of the SAR Shares shall vest on the one-year anniversary of the Vesting Commencement Date, with 27,500 of the SAR Shares vesting per month over the remaining 24 months, in each case provided that Grantee remains continuously employed with (or is providing continued service to) the Company through the applicable vesting date, inclusive; and provided further that if the Company terminates Grantee’s employment without Cause, or if Grantee terminates his employment with the Company for Good Reason (each as defined under that certain Employment Agreement, effective October 1, 2013, by and between the Company and Grantee (as may be amended or restated from time to time)) prior to the one-year anniversary of the Vesting Commencement Date, a total of 340,000 of the SAR Shares shall be deemed automatically vested.

 

Notwithstanding the foregoing, Grantee’s SAR Shares will become 100% vested upon the earlier to occur of: (i) Grantee’s Termination of Service as a result of Grantee’s Disability, death or Retirement; provided that Grantee has continuously served as a director, employee or Advisor of the Company for the two-year period immediately preceding Grantee’s Termination of Service; and (ii) as of immediately prior to, and contingent upon, a Qualified Change in Control; provided that Grantee remains continuously employed with (or is providing continued service to) the Company through immediately prior to the effectiveness of such Qualified Change in Control.

 

For purposes of this Award, a “Qualified Change in Control” means a Change in Control whereby (i) the acquiring party (or parties) in such Change in Control offers cash, in whole or in part, to some or all of the Company’s stockholders as consideration for the shares of capital stock of the Company held thereby, and (ii) the Fair Market Value as of the last trading day immediately preceding the Change in Control or the aggregate per share price payable by the acquiring party in such Change in Control for the Common Stock is greater than the Exercise Price.

 

Any fraction of a share that becomes exercisable on any date will be rounded down to the next lowest whole number and any fraction of a share shall be added to the portion of the SAR Shares becoming exercisable on the following vesting date.

 

Expiration Date October 4, 2023, subject to Section 6.

 

- 2 -
 

Section 3. Adjustments to Number of SAR Shares and Exercise Price. No shares of Common Stock will be issued and no cash will be paid to Grantee before the Award vests in accordance with the “Vesting Schedule” noted in Section 2 and is exercised. The amount Grantee receives upon exercise will equal the product of:

 

(a)the number of SAR Shares that Grantee designates for exercise, and

 

(b)the excess of 100% of the Fair Market Value of one share of Common Stock on the date of exercise over the Exercise Price stated in Section 2.

 

Section 4. Form of Payments to Grantee. Except with respect to an Automatic Exercise (as defined below), the Company will make any payment to Grantee under the Award, as determined by the Board or the Committee following the exercise, in the form of cash, net of any applicable tax withholding obligations or shares of Common Stock, with cash paid in lieu of fractional shares of Common Stock, based on the Fair Market Value on the date of exercise. Any shares of Common Stock that Grantee receives will be free from vesting restrictions (but subject to such legends as the Company determines to be appropriate). Notwithstanding the foregoing, the Company will not issue certificates representing shares of Common Stock issuable upon the exercise of the Award to Grantee unless Grantee has made arrangements satisfactory to the Board or the Committee to satisfy any applicable tax withholding obligations. Grantee may satisfy minimum withholding requirements through the surrender of shares of Common Stock that are both subject to the Award and that have a Fair Market Value equal to the minimum statutory tax withholding associated with the shares of Common Stock giving rise to the taxable income. Grantee or the Successor of the Participant has no right or any privilege of a stockholder of the Company in respect of any shares issuable on the exercise of the award unless and until such shares have been recorded on the Company’s official stockholder records as having been issued and transferred.

 

Section 5. Automatic Exercise. Notwithstanding anything herein to the contrary, this Award shall be deemed automatically exercised in full, without any further action on the part of Grantee or the Company, effective as of immediately prior to, and contingent upon, a Qualified Change in Control; provided that Grantee has remained continuously employed with (or has provided continued service to) the Company from the Grant Date through immediately prior to the effectiveness of such Qualified Change in Control (an “Automatic Exercise”). In the event of such Automatic Exercise, the Company will make a payment to Grantee under the Award in the form of cash, net of any applicable tax withholding obligations.

 

Section 6. Failure of Vesting Restrictions. By executing this Agreement, Grantee acknowledges and agrees that the Award will terminate prior to the Expiration Date as provided below:

 

(a) Termination of Service. Upon Grantee’s Termination of Service by the election of the Company for any reason other than Grantee’s death, Retirement or Disability (other than for Cause), Grantee may exercise the Award at any time within three months from Grantee’s Termination of Service, but only to the extent that, as of the date of Grantee’s Termination of Service, Grantee’s right to exercise the Award has vested and Grantee has not previously exercised the Award. Any portion of the Award unexercised following such period shall be forfeited as of the expiration date of such period. Notwithstanding the foregoing, if Grantee suffers a Termination of Service for Cause or the Termination of Service occurs by the election of Grantee (other than an election because of death, Retirement or Disability), Grantee’s unexercised Award as of the date of his or her Termination of Service shall be cancelled and forfeited as of such date.

 

- 3 -
 

(b) Death, Retirement or Disability. Upon Grantee’s Termination of Service by reason of Grantee’s death, Retirement or Disability, or if Grantee dies with exercise rights under Section 6(a), Grantee (or his or her beneficiary in the case of death) may exercise the Award at any time within 12 months from Grantee’s Termination of Service, but only to the extent that, at the date of Termination of Service, Grantee’s right to exercise the Award has vested and Grantee has not previously exercised the Award. Any portion of the Award unexercised following such period shall be forfeited as of the expiration date of such period.

 

Section 7. Exercise. Subject to the provisions hereof, including Section 2 and Section 5, the Award may be exercised in whole or in part at any time, within the period permitted for the exercise thereof, with respect to whole shares only. To exercise the Award, other than pursuant to an Automatic Exercise, Grantee or the Successor of the Participant must deliver a Notice of Exercise in the form attached hereto as Exhibit B (the “Notice of Exercise”) to the Company at its principal office together with such additional documents as the Company may then require. The Company will determine the amount of any applicable taxes which require withholding as a result of the exercise, and Grantee must provide for such taxes as required by Section 9 and the Plan.

 

Section 8. Nontransferability of Award. Except as the Company and Grantee may agree in accordance with Section 6.3 of the Plan, the Award may not be sold, pledged, assigned, hypothecated, transferred or disposed of by Grantee in any manner other than by will or the laws of descent and distribution. No transfer of any portion of the Award by will or the laws of descent and distribution shall be effective to bind the Company unless the Company is furnished with written notice thereof and appropriate documentation evidencing the rights of any Successor(s) of the Participant as the Committee deems necessary or desirable.

 

Section 9. Withholding Obligations.

 

(a) At the time Grantee exercises the Award, or this Award is otherwise deemed exercised pursuant to an Automatic Exercise, in either case, in whole or in part, or at any time thereafter as requested by the Company, Grantee hereby authorizes withholding from payroll and any other amounts payable to Grantee, and otherwise agree to make adequate provision for, any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of the Award. By exercising the Award, Grantee agrees that, as a condition to any exercise of the Award, the Company may require Grantee to enter into an arrangement providing for the payment by Grantee to the Company of any tax withholding obligation of the Company arising by reason of the exercise of the Award.

 

- 4 -
 

 

(b) Upon Grantee’s request and subject to approval by the Company, in its sole discretion, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to Grantee upon the exercise of the Award a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid variable award accounting). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of the Award, share withholding pursuant to the preceding sentence shall not be permitted unless Grantee makes a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of the Award. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of the Award that are otherwise issuable to Grantee upon such exercise. Any adverse consequences to Grantee arising in connection with such share withholding procedure shall be Grantee’s sole responsibility.

 

(c) Grantee may not exercise the Award unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, Grantee may not be able to exercise the Award when desired even though the Award is vested, and the Company shall have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein unless such obligations are satisfied.

 

Section 10. Miscellaneous Provisions.

 

(a) No Retention Rights. Nothing in this Agreement shall confer upon Grantee any right to continue in the employment or service of the Company for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company or of Grantee, which rights are hereby expressly reserved by each, to terminate his or her employment or service at any time and for any reason, with or without cause.

 

(b) Antidilution. In the event that any change in the outstanding shares of Common Stock of the Company (including an exchange of Common Stock for stock or other securities of another corporation) occurs by reason of a Common Stock dividend or split, recapitalization, merger, consolidation, combination, exchange of shares or other similar corporate changes, other than for consideration received by the Company therefore, the number of shares of stock granted hereunder or the Exercise Price may be appropriately adjusted by the Committee in its sole and absolute discretion, whose determination shall be conclusive, final and binding; provided, however that fractional shares shall be rounded to the nearest whole share. In the event of any other change in the Common Stock, the Committee shall in its sole discretion determine whether such change equitably requires a change in the number or type of shares of stock granted hereunder or the Exercise Price and any adjustment made by the Committee shall be conclusive, final and binding.

 

- 5 -
 

 

(c) Determination of Value. The Company makes no representation as to the value of the Award or whether Grantee will be able to realize any profit from it.

 

(d) Plan. The provisions of the Plan are incorporated by reference into these terms and conditions. To the extent any provision of this Agreement conflicts with the Plan, the terms of the Plan shall govern. Grantee acknowledges receipt of a copy of the Plan and represents that he has reviewed the Plan and is familiar with the terms and provisions thereof. Grantee hereby accepts this Agreement and the terms of the Plan.

 

(e) Notices. Any notice required by the terms of this Agreement shall be given in writing and shall be deemed effective upon personal delivery, upon deposit with the United States Postal Service, by registered or certified mail, with postage and fees prepaid or upon deposit with a reputable overnight courier. Notice shall be addressed to the Company at its principal executive office and to Grantee at the address most recently provided by Grantee to the Company.

 

(f) Blackout Periods. In connection with certain corporate events, the Company reserves the right to designate periods during which Grantee may not exercise the Award; provided that no such blackout period shall limit or delay an Automatic Exercise, as provided under Section 5.

 

(g) Entire Agreement; Amendments. This Agreement constitutes the entire contract between the parties hereto with regard to the subject matter hereof. This Agreement supersedes any other agreements, representations or understandings (whether oral or written and whether express or implied) which relate to the subject matter hereof. The Committee shall have authority, subject to the express provisions of the Plan, to interpret this Agreement and the Plan, to establish, amend and rescind any rules and regulations relating to the Plan, to modify the terms and provisions of this Agreement, and to make all other determinations in the judgment of the Committee necessary or desirable for the administration of the Plan. The Committee may correct any defect or supply any omission or reconcile any inconsistency in the Plan or in this Agreement in the manner and to the extent it shall deem necessary or desirable to carry it into effect. All action by the Committee under the provisions of this paragraph shall be final, conclusive and binding for all purposes.

 

(h) Change in Control. Unless provided otherwise in connection with the transaction resulting in the Change in Control, immediately preceding the occurrence of a Change in Control of the Company, any unvested portion of the Award shall immediately vest in full and to the extent not expired or previously exercised become immediately exercisable.

 

(i) Choice of Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, as such laws are applied to contracts entered into and performed in such State, without giving effect to the choice of law provisions thereof.

 

- 6 -
 

 

(j) Successors. This Agreement is personal to Grantee and, except as otherwise provided above, shall not be assignable by Grantee otherwise than by will or the laws of descent and distribution, without the written consent of the Company. This Agreement shall inure to the benefit of and be enforceable by Grantee’s legal representatives. This Agreement shall inure to the benefit of and be binding upon the Company and its successors. It shall not be assignable by the Company except in connection with the sale or other disposition of all or substantially all the assets or business of the Company.

 

(k) Severability. If any provision of this Agreement for any reason should be found by any court of competent jurisdiction to be invalid, illegal or unenforceable, in whole or in part, such declaration shall not affect the validity, legality or enforceability of any remaining provision or portion hereof, which remaining provision or portion hereof shall remain in full force and effect as if this Agreement had been adopted with the invalid, illegal or unenforceable provision or portion hereof eliminated.

 

(l) Headings. The headings and captions in this Agreement shall not be construed to limit or modify the terms or meaning of this Agreement.

 

[Remainder of Page Intentionally Left Blank]

 

- 7 -
 

BY GRANTEE’S SIGNATURE BELOW, along with the signature of the Company’s representative, Grantee and the Company agree that the Stock Appreciation Rights are awarded under and governed by the terms and conditions of this Agreement, the Plan and, in the event of exercise of the Award, the Notice of Exercise.

 

 

Transgenomic, INC.
 
 
By:  
 
Name: Rodney S. Markin, M.D., Ph.D.
 
Title: Chairman of the Board of Directors
 
GRANTEE
The undersigned Grantee hereby accepts the terms of this Agreement, the Plan and, in the event of exercise of the Award, the Notice of Exercise.
By:    
 
Name of Grantee: Paul Kinnon

  

 

 

 

[Signature Page to Stock Appreciation Rights Agreement]

 
 

Exhibit A

 

TRANSGENOMIC, INC.

 

2006 Equity Incentive Plan

 

 

 

 

 

 

 

 

A-1

 
 

Exhibit B

 

TRANSGENOMIC, INC.

 

STOCK APPRECIATION RIGHTS

 

NOTICE OF EXERCISE

 

 

 

Transgenomic, Inc.

12325 Emmet Street

Omaha, Nebraska 68164

 

  Date of Exercise: _______________

 

Ladies and Gentlemen:

 

This constitutes notice under my Stock Appreciation Rights Agreement with Transgenomic, Inc., a Delaware corporation (the “Company”), identified below that I elect to exercise my Stock Appreciation Rights with respect to the number of shares set forth below.

 

Grant Date of Stock Appreciation Rights Agreement:   October 4, 2013     
Number of shares as
to which SAR is
exercised:
  ___________________________
[Certificates to be
issued in name of:
  ___________________________]

 

By this exercise, I agree (i) to provide such additional documents as the Company may require pursuant to the terms of the Transgenomic, Inc. 2006 Equity Incentive Plan (the “Plan”), and (ii) that the Company will satisfy its obligations arising from this exercise notice through withholding a portion of the cash payment payable hereunder equal to the amount of such obligations and/or issuing shares of common stock of the Company (net of shares of common stock of the Company having a Fair Market Value (as defined in the Plan) equal to the minimum statutory taxes and withholding due; except to the extent the undersigned pays cash herewith to settle such obligations).

 

Very truly yours,
By:    
 
Name: Paul Kinnon
 

 

 

 

 

B-1

 

EX-10.4 5 v356113_ex10-4.htm EXHIBIT 10.4

EXHIBIT 10.4

 

 

 

Description: header2

 

TRANSGENOMIC, INC. 2006 EQUITY INCENTIVE PLAN

 

STOCK APPRECIATION RIGHTS AGREEMENT

 

THIS STOCK APPRECIATION RIGHTS AGREEMENT (this “Agreement”) is effective October 4, 2013 (the “Grant Date”) by and between Transgenomic, Inc., a Delaware corporation (the “Company”) and Mark Colonnese (“Grantee”).

 

WHEREAS, the Company sponsors and maintains the Transgenomic, Inc. 2006 Equity Incentive Plan, a copy of which is attached hereto as Exhibit A (the “Plan”); and

 

WHEREAS, Grantee, as an Eligible Person, has been selected to receive a grant of Stock Appreciation Rights under the Plan.

 

NOW, THEREFORE, the Company and Grantee hereby agree as follows:

 

Section 1. General. This Agreement and the Stock Appreciation Rights granted hereunder are subject in all respects to the terms and conditions of the Plan. Capitalized terms used in this Agreement without further definition shall have the same meanings given to such terms in the Plan. The award of Stock Appreciation Rights of the Company described herein (this “Award”) is conditioned on Grantee’s execution of the Award within ten (10) days after the Grant Date.

 

Section 2. Grant of Stock Appreciation Rights. The Company hereby awards to Grantee, as of the Grant Date, Stock Appreciation Rights with the following terms:

 

Grant Date October 4, 2013
Vesting Commencement Date October 4, 2013
Number of Shares measuring the value of the Award 660,000 Shares (the “SAR Shares”)
Exercise Price per SAR Share $[_____._____] per Share (the “Exercise Price”)

 

- 1 -
 

 

Vesting Schedule

224,400 of the SAR Shares shall vest on the one-year anniversary of the Vesting Commencement Date, with 18,150 of the SAR Shares vesting per month over the remaining 24 months, in each case provided that Grantee remains continuously employed with (or is providing continued service to) the Company through the applicable vesting date, inclusive; and provided further that if the Company terminates Grantee’s employment without Just Cause (as defined under that certain Employment Agreement, dated September 12, 2012, by and between the Company and Grantee, as amended (as may be amended or restated from time to time)) prior to the one-year anniversary of the Vesting Commencement Date, the SAR Shares shall be deemed to have vested on a monthly basis at a rate of 1/36th per month from the Vesting Commencement Date.

 

Notwithstanding the foregoing, Grantee’s SAR Shares will become 100% vested upon the earlier to occur of: (i) Grantee’s Termination of Service as a result of Grantee’s Disability, death or Retirement; provided that Grantee has continuously served as a director, employee or Advisor of the Company for the two-year period immediately preceding Grantee’s Termination of Service; and (ii) as of immediately prior to, and contingent upon, a Qualified Change in Control; provided that Grantee remains continuously employed with (or is providing continued service to) the Company through immediately prior to the effectiveness of such Qualified Change in Control.

 

For purposes of this Award, a “Qualified Change in Control” means a Change in Control whereby (i) the acquiring party (or parties) in such Change in Control offers cash, in whole or in part, to some or all of the Company’s stockholders as consideration for the shares of capital stock of the Company held thereby, and (ii) the Fair Market Value as of the last trading day immediately preceding the Change in Control or the aggregate per share price payable by the acquiring party in such Change in Control for the Common Stock is greater than the Exercise Price.

 

Any fraction of a share that becomes exercisable on any date will be rounded down to the next lowest whole number and any fraction of a share shall be added to the portion of the SAR Shares becoming exercisable on the following vesting date.

 

Expiration Date October 4, 2023, subject to Section 6.

- 2 -
 

 

Section 3. Adjustments to Number of SAR Shares and Exercise Price. No shares of Common Stock will be issued and no cash will be paid to Grantee before the Award vests in accordance with the “Vesting Schedule” noted in Section 2 and is exercised. The amount Grantee receives upon exercise will equal the product of:

 

(a)the number of SAR Shares that Grantee designates for exercise, and

 

(b)the excess of 100% of the Fair Market Value of one share of Common Stock on the date of exercise over the Exercise Price stated in Section 2.

 

Section 4. Form of Payments to Grantee. Except with respect to an Automatic Exercise (as defined below), the Company will make any payment to Grantee under the Award, as determined by the Board or the Committee following the exercise, in the form of cash, net of any applicable tax withholding obligations or shares of Common Stock, with cash paid in lieu of fractional shares of Common Stock, based on the Fair Market Value on the date of exercise. Any shares of Common Stock that Grantee receives will be free from vesting restrictions (but subject to such legends as the Company determines to be appropriate). Notwithstanding the foregoing, the Company will not issue certificates representing shares of Common Stock issuable upon the exercise of the Award to Grantee unless Grantee has made arrangements satisfactory to the Board or the Committee to satisfy any applicable tax withholding obligations. Grantee may satisfy minimum withholding requirements through the surrender of shares of Common Stock that are both subject to the Award and that have a Fair Market Value equal to the minimum statutory tax withholding associated with the shares of Common Stock giving rise to the taxable income. Grantee or the Successor of the Participant has no right or any privilege of a stockholder of the Company in respect of any shares issuable on the exercise of the award unless and until such shares have been recorded on the Company’s official stockholder records as having been issued and transferred.

 

Section 5. Automatic Exercise. Notwithstanding anything herein to the contrary, this Award shall be deemed automatically exercised in full, without any further action on the part of Grantee or the Company, effective as of immediately prior to, and contingent upon, a Qualified Change in Control; provided that Grantee has remained continuously employed with (or has provided continued service to) the Company from the Grant Date through immediately prior to the effectiveness of such Qualified Change in Control (an “Automatic Exercise”). In the event of such Automatic Exercise, the Company will make a payment to Grantee under the Award in the form of cash, net of any applicable tax withholding obligations.

 

Section 6. Failure of Vesting Restrictions. By executing this Agreement, Grantee acknowledges and agrees that the Award will terminate prior to the Expiration Date as provided below:

 

(a) Termination of Service. Upon Grantee’s Termination of Service by the election of the Company for any reason other than Grantee’s death, Retirement or Disability (other than for Cause), Grantee may exercise the Award at any time within three months from Grantee’s Termination of Service, but only to the extent that, as of the date of Grantee’s Termination of Service, Grantee’s right to exercise the Award has vested and Grantee has not previously exercised the Award. Any portion of the Award unexercised following such period shall be forfeited as of the expiration date of such period. Notwithstanding the foregoing, if Grantee suffers a Termination of Service for Cause or the Termination of Service occurs by the election of Grantee (other than an election because of death, Retirement or Disability), Grantee’s unexercised Award as of the date of his or her Termination of Service shall be cancelled and forfeited as of such date.

 

- 3 -
 

(b) Death, Retirement or Disability. Upon Grantee’s Termination of Service by reason of Grantee’s death, Retirement or Disability, or if Grantee dies with exercise rights under Section 6(a), Grantee (or his or her beneficiary in the case of death) may exercise the Award at any time within 12 months from Grantee’s Termination of Service, but only to the extent that, at the date of Termination of Service, Grantee’s right to exercise the Award has vested and Grantee has not previously exercised the Award. Any portion of the Award unexercised following such period shall be forfeited as of the expiration date of such period.

 

Section 7. Exercise. Subject to the provisions hereof, including Section 2 and Section 5, the Award may be exercised in whole or in part at any time, within the period permitted for the exercise thereof, with respect to whole shares only. To exercise the Award, other than pursuant to an Automatic Exercise, Grantee or the Successor of the Participant must deliver a Notice of Exercise in the form attached hereto as Exhibit B (the “Notice of Exercise”) to the Company at its principal office together with such additional documents as the Company may then require. The Company will determine the amount of any applicable taxes which require withholding as a result of the exercise, and Grantee must provide for such taxes as required by Section 9 and the Plan.

 

Section 8. Nontransferability of Award. Except as the Company and Grantee may agree in accordance with Section 6.3 of the Plan, the Award may not be sold, pledged, assigned, hypothecated, transferred or disposed of by Grantee in any manner other than by will or the laws of descent and distribution. No transfer of any portion of the Award by will or the laws of descent and distribution shall be effective to bind the Company unless the Company is furnished with written notice thereof and appropriate documentation evidencing the rights of any Successor(s) of the Participant as the Committee deems necessary or desirable.

 

Section 9. Withholding Obligations.

 

(a) At the time Grantee exercises the Award, or this Award is otherwise deemed exercised pursuant to an Automatic Exercise, in either case, in whole or in part, or at any time thereafter as requested by the Company, Grantee hereby authorizes withholding from payroll and any other amounts payable to Grantee, and otherwise agree to make adequate provision for, any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of the Award. By exercising the Award, Grantee agrees that, as a condition to any exercise of the Award, the Company may require Grantee to enter into an arrangement providing for the payment by Grantee to the Company of any tax withholding obligation of the Company arising by reason of the exercise of the Award.

- 4 -
 

 

(b) Upon Grantee’s request and subject to approval by the Company, in its sole discretion, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to Grantee upon the exercise of the Award a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid variable award accounting). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of the Award, share withholding pursuant to the preceding sentence shall not be permitted unless Grantee makes a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of the Award. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of the Award that are otherwise issuable to Grantee upon such exercise. Any adverse consequences to Grantee arising in connection with such share withholding procedure shall be Grantee’s sole responsibility.

 

(c) Grantee may not exercise the Award unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, Grantee may not be able to exercise the Award when desired even though the Award is vested, and the Company shall have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein unless such obligations are satisfied.

 

Section 10. Miscellaneous Provisions.

 

(a) No Retention Rights. Nothing in this Agreement shall confer upon Grantee any right to continue in the employment or service of the Company for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company or of Grantee, which rights are hereby expressly reserved by each, to terminate his or her employment or service at any time and for any reason, with or without cause.

 

(b) Antidilution. In the event that any change in the outstanding shares of Common Stock of the Company (including an exchange of Common Stock for stock or other securities of another corporation) occurs by reason of a Common Stock dividend or split, recapitalization, merger, consolidation, combination, exchange of shares or other similar corporate changes, other than for consideration received by the Company therefore, the number of shares of stock granted hereunder or the Exercise Price may be appropriately adjusted by the Committee in its sole and absolute discretion, whose determination shall be conclusive, final and binding; provided, however that fractional shares shall be rounded to the nearest whole share. In the event of any other change in the Common Stock, the Committee shall in its sole discretion determine whether such change equitably requires a change in the number or type of shares of stock granted hereunder or the Exercise Price and any adjustment made by the Committee shall be conclusive, final and binding.

 

- 5 -
 

(c) Determination of Value. The Company makes no representation as to the value of the Award or whether Grantee will be able to realize any profit from it.

 

(d) Plan. The provisions of the Plan are incorporated by reference into these terms and conditions. To the extent any provision of this Agreement conflicts with the Plan, the terms of the Plan shall govern. Grantee acknowledges receipt of a copy of the Plan and represents that he has reviewed the Plan and is familiar with the terms and provisions thereof. Grantee hereby accepts this Agreement and the terms of the Plan.

 

(e) Notices. Any notice required by the terms of this Agreement shall be given in writing and shall be deemed effective upon personal delivery, upon deposit with the United States Postal Service, by registered or certified mail, with postage and fees prepaid or upon deposit with a reputable overnight courier. Notice shall be addressed to the Company at its principal executive office and to Grantee at the address most recently provided by Grantee to the Company.

 

(f) Blackout Periods. In connection with certain corporate events, the Company reserves the right to designate periods during which Grantee may not exercise the Award; provided that no such blackout period shall limit or delay an Automatic Exercise, as provided under Section 5.

 

(g) Entire Agreement; Amendments. This Agreement constitutes the entire contract between the parties hereto with regard to the subject matter hereof. This Agreement supersedes any other agreements, representations or understandings (whether oral or written and whether express or implied) which relate to the subject matter hereof. The Committee shall have authority, subject to the express provisions of the Plan, to interpret this Agreement and the Plan, to establish, amend and rescind any rules and regulations relating to the Plan, to modify the terms and provisions of this Agreement, and to make all other determinations in the judgment of the Committee necessary or desirable for the administration of the Plan. The Committee may correct any defect or supply any omission or reconcile any inconsistency in the Plan or in this Agreement in the manner and to the extent it shall deem necessary or desirable to carry it into effect. All action by the Committee under the provisions of this paragraph shall be final, conclusive and binding for all purposes.

 

(h) Change in Control. Unless provided otherwise in connection with the transaction resulting in the Change in Control, immediately preceding the occurrence of a Change in Control of the Company, any unvested portion of the Award shall immediately vest in full and to the extent not expired or previously exercised become immediately exercisable.

 

(i) Choice of Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, as such laws are applied to contracts entered into and performed in such State, without giving effect to the choice of law provisions thereof.

 

- 6 -
 

(j) Successors. This Agreement is personal to Grantee and, except as otherwise provided above, shall not be assignable by Grantee otherwise than by will or the laws of descent and distribution, without the written consent of the Company. This Agreement shall inure to the benefit of and be enforceable by Grantee’s legal representatives. This Agreement shall inure to the benefit of and be binding upon the Company and its successors. It shall not be assignable by the Company except in connection with the sale or other disposition of all or substantially all the assets or business of the Company.

 

(k) Severability. If any provision of this Agreement for any reason should be found by any court of competent jurisdiction to be invalid, illegal or unenforceable, in whole or in part, such declaration shall not affect the validity, legality or enforceability of any remaining provision or portion hereof, which remaining provision or portion hereof shall remain in full force and effect as if this Agreement had been adopted with the invalid, illegal or unenforceable provision or portion hereof eliminated.

 

(l) Headings. The headings and captions in this Agreement shall not be construed to limit or modify the terms or meaning of this Agreement.

 

[Remainder of Page Intentionally Left Blank]

 

- 7 -
 

BY GRANTEE’S SIGNATURE BELOW, along with the signature of the Company’s representative, Grantee and the Company agree that the Stock Appreciation Rights are awarded under and governed by the terms and conditions of this Agreement, the Plan and, in the event of exercise of the Award, the Notice of Exercise. 

 

Transgenomic, INC.
 
 
By:  
 
Name: Rodney S. Markin, M.D., Ph.D.
 
Title: Chairman of the Board of Directors
 
GRANTEE
The undersigned Grantee hereby accepts the terms of this Agreement, the Plan and, in the event of exercise of the Award, the Notice of Exercise.
By:    
 
Name of Grantee: Mark Colonnese
 

  

 

[Signature Page to Stock Appreciation Rights Agreement]

 

 
 

 

Exhibit A

 

TRANSGENOMIC, INC.

 

2006 Equity Incentive Plan

 

 

 

 

 

 

 

 

A-1

 

 
 

Exhibit B

 

TRANSGENOMIC, INC.

 

STOCK APPRECIATION RIGHTS

 

NOTICE OF EXERCISE

 

Transgenomic, Inc.

12325 Emmet Street

Omaha, Nebraska 68164

 

  Date of Exercise: _______________

 

Ladies and Gentlemen:

 

This constitutes notice under my Stock Appreciation Rights Agreement with Transgenomic, Inc., a Delaware corporation (the “Company”), identified below that I elect to exercise my Stock Appreciation Rights with respect to the number of shares set forth below.

 

Grant Date of Stock Appreciation Rights Agreement:   October 4, 2013     
Number of shares as
to which SAR is
exercised:
  ___________________________
[Certificates to be
issued in name of:
  ___________________________]

 

By this exercise, I agree (i) to provide such additional documents as the Company may require pursuant to the terms of the Transgenomic, Inc. 2006 Equity Incentive Plan (the “Plan”), and (ii) that the Company will satisfy its obligations arising from this exercise notice through withholding a portion of the cash payment payable hereunder equal to the amount of such obligations and/or issuing shares of common stock of the Company (net of shares of common stock of the Company having a Fair Market Value (as defined in the Plan) equal to the minimum statutory taxes and withholding due; except to the extent the undersigned pays cash herewith to settle such obligations). 

 

Very truly yours,
By:    
 
Name: Mark Colonnese
 

 

 

 

B-1

 

EX-10.5 6 v356113_ex10-5.htm EXHIBIT 10.5

EXHIBIT 10.5

 

 

 

Description: header2

 

 

TRANSGENOMIC, INC. 2006 EQUITY INCENTIVE PLAN

 

FORM OF

 

STOCK APPRECIATION RIGHTS AGREEMENT

 

 

 

THIS STOCK APPRECIATION RIGHTS AGREEMENT (this “Agreement”) is effective _______________, 20__ (the “Grant Date”) by and between Transgenomic, Inc., a Delaware corporation (the “Company”) and ____________ (“Grantee”).

 

WHEREAS, the Company sponsors and maintains the Transgenomic, Inc. 2006 Equity Incentive Plan, a copy of which is attached hereto as Exhibit A (the “Plan”); and

 

WHEREAS, Grantee, as an Eligible Person, has been selected to receive a grant of Stock Appreciation Rights under the Plan.

 

NOW, THEREFORE, the Company and Grantee hereby agree as follows:

 

Section 1. General. This Agreement and the Stock Appreciation Rights granted hereunder are subject in all respects to the terms and conditions of the Plan. Capitalized terms used in this Agreement without further definition shall have the same meanings given to such terms in the Plan. The award of Stock Appreciation Rights of the Company described herein (this “Award”) is conditioned on Grantee’s execution of the Award within ten (10) days after the Grant Date.

 

Section 2. Grant of Stock Appreciation Rights. The Company hereby awards to Grantee, as of the Grant Date, Stock Appreciation Rights with the following terms:

 

Grant Date ________________, 20__
Vesting Commencement Date ________________, 20__
Number of Shares measuring the value of the Award __________ Shares (the “SAR Shares”)
Exercise Price per SAR Share $_____._____ per Share (the “Exercise Price”)

 

 
 

 

Vesting Schedule

34% of the SAR Shares vest on the one-year anniversary of the Vesting Commencement Date and 33% of the SAR Shares vest on each of the two-year anniversary and three-year anniversary of the Vesting Commencement Date, in each case provided that Grantee remains continuously employed with (or is providing continued service to) the Company through the applicable vesting date, inclusive.

 

Any fraction of a share that becomes exercisable on any date will be rounded down to the next lowest whole number and any fraction of a share shall be added to the portion of the SAR Shares becoming exercisable on the following vesting date.

 

Expiration Date ________________, 20__, subject to Section 5.

 

Section 3. Adjustments to Number of SAR Shares and Exercise Price. No shares of Common Stock will be issued and no cash will be paid to Grantee before the Award vests in accordance with the “Vesting Schedule” noted in Section 2 and is exercised. The amount Grantee receives upon exercise will equal the product of:

 

(a)the number of SAR Shares that Grantee designates for exercise, and

 

(b)the excess of 100% of the Fair Market Value of one share of Common Stock on the date of exercise over the Exercise Price stated in Section 2.

 

Section 4. Form of Payments to Grantee. The Company will make any payment to Grantee under the Award, as determined by the Board or the Committee following the exercise, in the form of cash, net of any applicable tax withholding obligations or shares of Common Stock, with cash paid in lieu of fractional shares of Common Stock, based on the Fair Market Value on the date of exercise. Any shares of Common Stock that Grantee receives will be free from vesting restrictions (but subject to such legends as the Company determines to be appropriate). Notwithstanding the foregoing, the Company will not issue certificates representing shares of Common Stock issuable upon the exercise of the Award to Grantee unless Grantee has made arrangements satisfactory to the Board or the Committee to satisfy any applicable tax withholding obligations. Grantee may satisfy minimum withholding requirements through the surrender of shares of Common Stock that are both subject to the Award and that have a Fair Market Value equal to the minimum statutory tax withholding associated with the shares of Common Stock giving rise to the taxable income. Grantee or the Successor of the Participant has no right or any privilege of a stockholder of the Company in respect of any shares issuable on the exercise of the award unless and until such shares have been recorded on the Company’s official stockholder records as having been issued and transferred.

 

Section 5. Failure of Vesting Restrictions. By executing this Agreement, Grantee acknowledges and agrees that the Award will terminate prior to the Expiration Date as provided below:

 

- 2 -
 

 

(a) Termination of Service. Upon Grantee’s Termination of Service by the election of the Company for any reason other than Grantee’s death, Retirement or Disability (other than for Cause), Grantee may exercise the Award at any time within three months from Grantee’s Termination of Service, but only to the extent that, as of the date of Grantee’s Termination of Service, Grantee’s right to exercise the Award has vested and Grantee has not previously exercised the Award. Any portion of the Award unexercised following such period shall be forfeited as of the expiration date of such period. Notwithstanding the foregoing, if Grantee suffers a Termination of Service for Cause or the Termination of Service occurs by the election of Grantee (other than an election because of death, Retirement or Disability), Grantee’s unexercised Award as of the date of his or her Termination of Service shall be cancelled and forfeited as of such date.

 

(b) Death, Retirement or Disability. Upon Grantee’s Termination of Service by reason of Grantee’s death, Retirement or Disability, or if Grantee dies with exercise rights under Section 5(a), Grantee (or his or her beneficiary in the case of death) may exercise the Award at any time within 12 months from Grantee’s Termination of Service, but only to the extent that, at the date of Termination of Service, Grantee’s right to exercise the Award has vested and Grantee has not previously exercised the Award. Any portion of the Award unexercised following such period shall be forfeited as of the expiration date of such period.

 

Section 6. Exercise. Subject to the provisions hereof, the Award may be exercised in whole or in part at any time, within the period permitted for the exercise thereof, with respect to whole shares only. To exercise the Award, Grantee or the Successor of the Participant must deliver a Notice of Exercise in the form attached hereto as Exhibit B (the “Notice of Exercise”) to the Company at its principal office together with such additional documents as the Company may then require. The Company will determine the amount of any applicable taxes which require withholding as a result of the exercise, and Grantee must provide for such taxes as required by Section 8 and the Plan.

 

Section 7. Nontransferability of Award. Except as the Company and Grantee may agree in accordance with Section 6.3 of the Plan, the Award may not be sold, pledged, assigned, hypothecated, transferred or disposed of by Grantee in any manner other than by will or the laws of descent and distribution. No transfer of any portion of the Award by will or the laws of descent and distribution shall be effective to bind the Company unless the Company is furnished with written notice thereof and appropriate documentation evidencing the rights of any Successor(s) of the Participant as the Committee deems necessary or desirable.

 

Section 8. Withholding Obligations.

 

(a) At the time Grantee exercises the Award, in whole or in part, or at any time thereafter as requested by the Company, Grantee hereby authorizes withholding from payroll and any other amounts payable to Grantee, and otherwise agree to make adequate provision for, any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of the Award. By exercising the Award, Grantee agrees that, as a condition to any exercise of the Award, the Company may require Grantee to enter into an arrangement providing for the payment by Grantee to the Company of any tax withholding obligation of the Company arising by reason of the exercise of the Award.

 

- 3 -
 

(b) Upon Grantee’s request and subject to approval by the Company, in its sole discretion, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to Grantee upon the exercise of the Award a number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid variable award accounting). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of the Award, share withholding pursuant to the preceding sentence shall not be permitted unless Grantee makes a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to accelerate the determination of such tax withholding obligation to the date of exercise of the Award. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined as of the date of exercise of the Award that are otherwise issuable to Grantee upon such exercise. Any adverse consequences to Grantee arising in connection with such share withholding procedure shall be Grantee’s sole responsibility.

 

(c) Grantee may not exercise the Award unless the tax withholding obligations of the Company and/or any Affiliate are satisfied. Accordingly, Grantee may not be able to exercise the Award when desired even though the Award is vested, and the Company shall have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein unless such obligations are satisfied.

 

Section 9. Miscellaneous Provisions.

 

(a) No Retention Rights. Nothing in this Agreement shall confer upon Grantee any right to continue in the employment or service of the Company for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company or of Grantee, which rights are hereby expressly reserved by each, to terminate his or her employment or service at any time and for any reason, with or without cause.

 

(b) Antidilution. In the event that any change in the outstanding shares of Common Stock of the Company (including an exchange of Common Stock for stock or other securities of another corporation) occurs by reason of a Common Stock dividend or split, recapitalization, merger, consolidation, combination, exchange of shares or other similar corporate changes, other than for consideration received by the Company therefore, the number of shares of stock granted hereunder or the Exercise Price may be appropriately adjusted by the Committee in its sole and absolute discretion, whose determination shall be conclusive, final and binding; provided, however that fractional shares shall be rounded to the nearest whole share. In the event of any other change in the Common Stock, the Committee shall in its sole discretion determine whether such change equitably requires a change in the number or type of shares of stock granted hereunder or the Exercise Price and any adjustment made by the Committee shall be conclusive, final and binding.

 

- 4 -
 

(c) Determination of Value. The Company makes no representation as to the value of the Award or whether Grantee will be able to realize any profit from it.

 

(d) Plan. The provisions of the Plan are incorporated by reference into these terms and conditions. To the extent any provision of this Agreement conflicts with the Plan, the terms of the Plan shall govern. Grantee acknowledges receipt of a copy of the Plan and represents that he has reviewed the Plan and is familiar with the terms and provisions thereof. Grantee hereby accepts this Agreement and the terms of the Plan.

 

(e) Notices. Any notice required by the terms of this Agreement shall be given in writing and shall be deemed effective upon personal delivery, upon deposit with the United States Postal Service, by registered or certified mail, with postage and fees prepaid or upon deposit with a reputable overnight courier. Notice shall be addressed to the Company at its principal executive office and to Grantee at the address most recently provided by Grantee to the Company.

 

(f) Blackout Periods. In connection with certain corporate events, the Company reserves the right to designate periods during which Grantee may not exercise the Award.

 

(g) Entire Agreement; Amendments. This Agreement constitutes the entire contract between the parties hereto with regard to the subject matter hereof. This Agreement supersedes any other agreements, representations or understandings (whether oral or written and whether express or implied) which relate to the subject matter hereof. The Committee shall have authority, subject to the express provisions of the Plan, to interpret this Agreement and the Plan, to establish, amend and rescind any rules and regulations relating to the Plan, to modify the terms and provisions of this Agreement, and to make all other determinations in the judgment of the Committee necessary or desirable for the administration of the Plan. The Committee may correct any defect or supply any omission or reconcile any inconsistency in the Plan or in this Agreement in the manner and to the extent it shall deem necessary or desirable to carry it into effect. All action by the Committee under the provisions of this paragraph shall be final, conclusive and binding for all purposes.

 

(h) Change in Control. Unless provided otherwise in connection with the transaction resulting in the Change in Control, immediately preceding the occurrence of a Change in Control of the Company, any unvested portion of the Award shall immediately vest in full and to the extent not expired or previously exercised become immediately exercisable.

 

- 5 -
 

(i) Choice of Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, as such laws are applied to contracts entered into and performed in such State, without giving effect to the choice of law provisions thereof.

 

(j) Successors. This Agreement is personal to Grantee and, except as otherwise provided above, shall not be assignable by Grantee otherwise than by will or the laws of descent and distribution, without the written consent of the Company. This Agreement shall inure to the benefit of and be enforceable by Grantee’s legal representatives. This Agreement shall inure to the benefit of and be binding upon the Company and its successors. It shall not be assignable by the Company except in connection with the sale or other disposition of all or substantially all the assets or business of the Company.

 

(k) Severability. If any provision of this Agreement for any reason should be found by any court of competent jurisdiction to be invalid, illegal or unenforceable, in whole or in part, such declaration shall not affect the validity, legality or enforceability of any remaining provision or portion hereof, which remaining provision or portion hereof shall remain in full force and effect as if this Agreement had been adopted with the invalid, illegal or unenforceable provision or portion hereof eliminated.

 

(l) Headings. The headings and captions in this Agreement shall not be construed to limit or modify the terms or meaning of this Agreement.

 

[Remainder of Page Intentionally Left Blank]

 

- 6 -
 

 

BY GRANTEE’S SIGNATURE BELOW, along with the signature of the Company’s representative, Grantee and the Company agree that the Stock Appreciation Rights are awarded under and governed by the terms and conditions of this Agreement, the Plan and, in the event of exercise of the Award, the Notice of Exercise.

 

 

Transgenomic, INC.
 
 
By:  
 
Name:
 
Title:
 
GRANTEE
The undersigned Grantee hereby accepts the terms of this Agreement, the Plan and, in the event of exercise of the Award, the Notice of Exercise.
By:    
 
Name of Grantee:
 

 

 

 

 

[Signature Page to Stock Appreciation Rights Agreement]

 
 

Exhibit A

 

TRANSGENOMIC, INC.

 

2006 Equity Incentive Plan

 

 

 

 

 

 

 

1.

 
 

Exhibit B

 

TRANSGENOMIC, INC.

 

STOCK APPRECIATION RIGHTS

 

NOTICE OF EXERCISE

 

Transgenomic, Inc.

12325 Emmet Street

Omaha, Nebraska 68164

 

  Date of Exercise: _______________

 

Ladies and Gentlemen:

 

This constitutes notice under my Stock Appreciation Rights Agreement with Transgenomic, Inc., a Delaware corporation (the “Company”), identified below that I elect to exercise my Stock Appreciation Rights with respect to the number of shares set forth below.

 

Grant Date of Stock Appreciation Rights Agreement: ___________________________
Number of shares as
to which SAR is
exercised:
___________________________
Certificates to be
issued in name of:
___________________________

 

By this exercise, I agree (i) to provide such additional documents as the Company may require pursuant to the terms of the Transgenomic, Inc. 2006 Equity Incentive Plan (the “Plan”), and (ii) that the Company will satisfy its obligations arising from this exercise notice through withholding a portion of the cash payment payable hereunder equal to the amount of such obligations and/or issuing shares of common stock of the Company (net of shares of common stock of the Company having a Fair Market Value (as defined in the Plan) equal to the minimum statutory taxes and withholding due; except to the extent the undersigned pays cash herewith to settle such obligations).

 

Very truly yours,
By:    
 
Name:
 

 

 

 

1.

 

EX-99.1 7 v356113_ex99-1.htm EXHIBIT 99.1

EXHIBIT 99.1

 

Transgenomic Announces Executive Changes

 

Paul Kinnon Named President, Chief Executive Officer and Director

 

OMAHA, Neb. (Sept 30, 2013) -- Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that Paul Kinnon has been named President, Chief Executive Officer and a Director, replacing Craig J. Tuttle, effective today.

 

Mr. Kinnon brings over two decades of business and scientific leadership in the biotechnology and pharmaceutical industries to Transgenomic, with a proven track record of developing and launching life science products. Most recently, he has provided commercial and strategic consultancy services to a variety of life science companies and investors, including Transgenomic. With broad experience covering clinical diagnostic, core life science research and applied markets, his appointment strengthens the executive leadership team and adds significant commercial, operational, and scientific expertise.

 

Rodney S. Markin, M.D., Ph.D., Chairman of Transgenomic commented: “Paul has a demonstrable history of success in building teams, forming strategic partnerships and leading global organizations. He has also played a pivotal role in the successful growth and development of many innovation-driven companies. We anticipate that the Board’s appointment of Paul as CEO will allow Transgenomic to leverage the Company’s leading assets, talent and business partners.” Dr. Markin added: “We thank Craig for his service to the Company and wish him well in his future endeavors.”

 

“Transgenomic is an exciting story, with a lot of potential for growth, particularly in the area of innovative genetic testing and services,” said Mr. Kinnon. “We have clear strengths in our tools, technologies, world class clinical and research services, and a terrific team of motivated people. I look forward to leading the Transgenomic team as we refine and implement strategies designed to better address our many promising market opportunities and create value for all of our stakeholders.”

 

Before joining Transgenomic, Mr. Kinnon was President and CEO of ZyGEM Corporation Limited, which he transformed from a local New Zealand reagent firm into a global company developing breakthrough analytic systems. Mr. Kinnon joined ZyGEM in 2007 from Invitrogen Corp. (now Life Technologies), where he held the positions of Vice President of Global Strategic Alliances and Vice President and General Manager of the Applied Markets Business Unit. Previously, Mr. Kinnon held business, sales and marketing roles of increasing responsibility at Guava Technologies, Cellomics, and other life science companies.

 

About Transgenomic, Inc.

 

Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases. The Company has three complementary business divisions: Clinical Laboratories, Pharmacogenomic Services and Diagnostic Tools, which provide specialized diagnostic tests, contract research services for drug development, and equipment, reagents and other consumables for clinical and research applications in molecular testing and cytogenetics.

 

Forward-Looking Statements

 

Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

 

 

Contact:

Investor Contact:
Argot Partners
David Pitts, 212-600-1902
david@argotpartners.com

 

or

Company Contact:
Transgenomic, Inc.
Investor Relations, 402-452-5416
investorrelations@transgenomic.com

 

 
 

 

 

 

GRAPHIC 8 image_001.jpg GRAPHIC begin 644 image_001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX. M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_ MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"``W`G`#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#@Z*.E:GA[ M0KCQ#JB6EOA5^])(>B+Z_6OH')15V>2HMNR*5G8W.H3>5:0/-)Z(,XK6_P"$ M2NTM3///#&H.".6(/I]:]2M=(@TK3ET_2[/=G#/+G:I]W?JWT%9D@62X\NS0 M:C=I\OF;=MO;^P'3^M<3Q3D]-CU:&!@U>H<#/X3N(GC2.Z@D>3[BG*D_G63> M6%S82F.ZB:-O?H?QKT"\6+3IV,TIO=2?C:G1?\!5.6%;6RF?4T$K7`QY;?T_ MQK2-66YO4RN$XWI.S.#I0"3P*TM0T:6P9'<%89%W*3U'L:S!=/YFVVA,F/12 M2:U=6*U/)6'GS.-MB>*T>0]*T(-,8X^4U=@FM;73X[BZBD$C#_5["*J7>M7A M0B&W:WB]=AS^=:KDM=NYRR=2[BD6Q8)`FZ9E0?[1Q4,E[80'&\R$?W!G]:Q6 M>6XD^=GD<_4FF;6#;2IW9QC'-7[2VQ*IM[LVX[Y+D?NHR@'7-6X_N,S#.T$U ME:=&X+*48-G[I!S^5:\2,T,H56)VG@#-?/XK%5EB/=D34A;1&2-8!/S0#'L: M>NJ6[??C=?UK*VD'!!!Z8QS3Y8)8,>=%)'NY&]2,U[ZJ/J:>S1L)+;3_`')% MSZ'BDDM%8=!61]GF(SY$N/78<4^*>X@7JG'KCBJ+V\D:[BC;?[V#C\ZJ]M&:K78CHISH\9^=&7O\PQ2M!+&JEXI M%#_=+*0&^E.Z%9C**UM5\,:IHMG;W5_;^7%/]TA@<'T/H:R:2DI:H;36C"BG M+&SG@5=MM.>5@`I)/;%%^PMMRDJ,QX%6(K)FZBM^'03%&)+EDAC]7.*BFU33 M;+Y8$:X<=^BU7+W9G[6^D5P_[Y-*)K1Q\LR?CQ6!11[3R#V?F=#Y$;CY&5OH:C>R7TK#5F5AM)!] MC6MI!EFNTC,C%.^:CVL6[-';1R^I4AS1D,ET\'H*IR6;ITYK2N-4CBNY(O+) M16(R#S4L<]O;G&!W)K.I5C"/-+83:CJS M,6)FZ"IDLV;J#6_'I4$/,TRH@&2S#I3)M2TFTR(A)RYS.P'HO%;I070+U&: MHTPCJE*;`*,D`"L%[J>3[\TA^K5&TCG`+M@^]$JD8J]C2C1G4FHW-[R8=V/, M3/IFE-B#_#Q6'&.14K7=Q&^$F<`=LTH55+='5B<"Z,.92--K!3_#5=].'85" MFL72GYF5Q_M"K":VI_UL'XJ:OEILX;U$5)+!UZ57>)T^\*W8KNTN.%<*WHW% M/>T5AT!%#I?RL%5_F1SE%:L^F@\KQ5"6UDB)R.*S=UN:)I[$-%%%`PHH`)/% M31VS/VI706(:<$9N@K1M],>1@%0DGL!6Q%X>1$1Z;:VM3['!^\)&TT>E0MIGI4P\029^>!" M/8XJ5-1.JFN@6\L9ONR@'T;BI&M$D7*D M,/;FCV79A[7NC'N+$KD@5Z1\/-/&G:&ER+033W3[RS$`!1P/\>E>`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`&"M_+_`"*Q/#MU8PZ,\-S=S:=.]P&6[1"58#^`GT]JP-%U368=1O[Z M']W<7#LLZ[?ER>HQ5VUO;_3K"2%$C>'/F>7/$)%#`=0.QKQJLX0J\MS.>)I* M:ON;.E:6S?%"Y?5DM9ITM?M$31)A)#P`V/7%<[='6=2\$7\MQ);7EK'.9#)) M)NFA.<8QVS63'XBUJ]\2KJ=L[MJ)X584SP!]T+Z8[4R_\47UY8S60CMK6"9R M\T=O%L\QO]KUKUE1G=/T-?:1LSN?%UX]IH&C>5K4NGL;`8A13^_.T<$C@?C4 M7AD6.H>![+1M2PD>H23)%+_U@@GMK"98(Q%&9(`Q50,=:S5 MU.]NK*STR$9$,QD@"#Y]['U_*A4)\MGIJ-U8W/4--TO[/K.DZ??A=T-JJ,.S M%2V>.3*.?E3:V%(].*Y*SUK5=3OY7U0F.]M0L6`NUE M(]?>M*YU*_N89DDGC591B4Q0A&E&.C,/_K5XE2LJ55J3UN<3Q5*G4:??[]"? M0(5UOP`U@5'VEVEEA'JR,./UH\56D5OX`LK.+'[FZ5)".[@$M^N?RKA;3Q5J M.CW$"V;QJ+.24Q[ES]_[V?6FW'BW4;K318S-&T/GF?.WYMQ))Y_$U[2I5)-- M[;G6JD.73>QZ%J^GV^H_$'P]%=JK0K;!RK=&(!(!_$5SLVLWD]QXDL[FPGU& M(2L4*]+3:6PP]!T_*J,&OW_B+4[=B2;^)0L(A7!`7GCWJS>:AJ^IPW<<"Q`R MKNNG@B"O(H[N1U%4L/-)-_\`#![:+=C&UKQ9J'B"PM[2Z6()"V[**06.,9-9 M,,(:0*QY)P*=*CVZ'$>35**_*3J63:0<_2JOS'DU#=>)K6R4Q:/;C=C!FD'/X"L"]U"YU"7S+J9I".!GH!]*K5 MUJ]CSO9W?O,GN[ZYOI"]S,\A/J>/RJ"BBF6DEL7;+_5GZU<_@;_=-5=-ADF# M"-"Q'7%:)LYXT8O$X&.N*^=Q4DJ[]2922=KG/T4K?>/UI*^A6Q84444P%7EA M71:#%Y<4UP?X5P*Y^,9?BNHVBS\/OV8KG\ZR2]YL^BP:Y:%_(Y>5_,F=_P"\ MQ-,Z'(HHK4^>D[MLMP:E-#@,=Z^C5IP7D%V,9VO_`'6K!HJU-HS<$SAI^H^)+J2+[/:H+2'&&"?>;\:S::= MI$MM_":3VNEZ,O\`Q,+@/,/^6,7)'U]*EM[B*ZA$L`VQGH/2N,))))))/4FM MOP[X=04A^\*6DZL*BI\)TX/^*B> M,0%3VUU<0N!$[(\8SR*R9XA&V8SE#^8^M<=.=2+Y*FGGW*LY[LVKGQ;<;2FGP M16B>H&6_,UC7%W<7;E[B:21CW9LU#1718M12"KVF-B1E]>:HU8L6"W*Y[\5% M17BSJPDN6M%FVO2L?4O^/L_2M<=*R-2'^E?A6%+XCV,R_@_,J4445U'SX444 M4P"I(IY86S%(RGV-1T4"MW%`)/`S7HG@O4!_9<:R2%);0X`+8&T]#COZ5E:= MX1D90\P$:>K5=N;_`$GP^N(7,MR/[O?V/M7/7I^TC9;E4<0H3T.O3Q$5@$-K M:F4J?E:/Y%7\3_2GW.G_`-JP)%JD\L;N/,6-)/DX'`.>3FL+3M775(TFMI8A M&""ZGEU]1CM70W"I+J7VJS*W6_.UA(/D..F,\5Y;]UV/;C);Q.9$TUQ'Y&EP MBVMQP9F7&?H/ZU2)M[25DM5-W=_Q2,<@?4]JT[JTEE4B[O(XU[6]N2[M]2*R M+]%M2T&Y%0?\LH@1_P!]'O\`2MH:Z'5&:CK)V1G7L^U9))&\Z5@5W]E/H*R_ MDC-NLI58VE4.6&0%SR:6ZN)&FRZ8C7[H':J>H3+*8PG0#-=48/FU.;$8NG.G M)P?D=EX@U?0G.H7,0TZZN'N8X[950G;"!RV./\BE4>$XY;J,3Z>UN6A6V)R7 M5<@R.Q]>O%FZ\,3*["VTYRM^S1PAC&3;@<9/N?6KDTF MEZ;H.J3V3Q/975Q#:B18-IV_><>Y`[^U>;59N=1N[R-([BXDDC3[JD\#\/ZU M+PKO\6A2KJVVIZ#87&@17DR!XOL9N4,#0AL+$!\V\^K<#US4]MLO^X?Y5\]6Q'+7<+;.QYM3'VJ64 M$1V][X9B:"=7LH)XXKACY+,IW$XB7/7..\@_P!#>/R8(XI(E)DD MD)'F,OKBN"IT4KP2K+$[)(ARK*<$&OH5AG:ZD>BJZ[':^(+'2K3PS?7%I%:L MLEZL%F\8.Y449;)/.?6I/`VJ:1IVE$:A=VD,QO4D<3+\WEJ,\''][%<;>:E> M:@P-YF\]*K52H2=/EDQ.JE/F2/1K+5-%NY;.XNY8%EFFFDO6A!RJD_( M'_J:C2X:?S#BVV)PK0%BK]\_-[8'%(B/:OGLPDJ=5TTCSL M9B5?DY=^I5U:;PFL6H-;&!IDDBEBC5#\W'S1`_7DGTJM(_AT0/L2"6)['"JJ MD2FZ)Y/^R!^6*PDTF6ZO7$:$Y8]JWHM%L])@$^J3*BCG8#R:]VGAVXIN3.UX MJ-K6-739M*L]81].2U$<-CM2>.-MTMP5P<'ZG]*9/JFB:1I^I1V5["7DMTBC M3!\QCGYR<]^",5SFI>+I&0V^E1_9H,8W?Q&N<9F=BSL2QY))R36BPVM[C5=R M6J.CC6VU"+=$1GTK,OM'(.2N#ZU1CE>%P\;%6'<&MVQUR*91%?*!VW5VR4*B MM(YTYTG>)@M&T9PPIM=7=Z*L\1EMR)$//'45@7&GO$3@5'*XE*HI%.BE*E3@ MC%)04=#X5/-P/I722SCV%=,?]0WT-?(9EIBV>3B=*IYY+_K M7_WC3:?+_KI/]XTROK8?"CU5L%%%%4,W]!TN&]1#*IW%NH.*VO$]M%::(<;B M6(`&:C\*1?Z,K>U-\<3XABA'KBL8[GTD_#![X%Q<;&RO\`=-:\UU:1Y#@T M[Q&W-C)`QRIP*@AD:&4,I((]*ZZVN++6XMK$1S^I[_6LK4]"DMG/RX]".AK. M=.Z:Z#C43=I%,],U5N1\X;UJPIVJ%?@BH[@9BSZ&O%PZ=*NDS:VA5HHHKVB0 MK0TRSBNMQE!X/?6QH0X?ZUG5V._+5>NDRW-I%O%:22!G!"Y'-)"G0\L?05UUKI M8MSMR"@Z&HM`TS[%:>8X_?2\GV'I5J^N-L;`2"-!]]R>@]J^:Q-2IC\1[*CL MOZN>;6K2J3Y([%34+UR?LMD"6/#,.U43#::4GF7K[I3R(E.6/U]*JW.MK"IB MTY2N>LK#YC]*QF9G8L[%F/4FO=PN%AA8]5;:^FM7!C8D=U/0U7HKI3ML;\JM8ZFRU.VOD"2C#=U/4?2H]0T+*&6 MW.Y/45S0)!!!P16YI/B&2V<)<'*]-W^-6VIJTC)PE!WB8\T+PMAA4==Q<:;: MZO`9;3:)",E/7Z5RE[ILMK(05.!V]*AIHTA44O4I4Y',;AAU'--HJ7JC2+Y9 M)EG^U9^P4#Z5'-6WD#PNR,.X-:\'BW48 M`G,;%#D$#:?THHJ94X3^)&D:DX?"R]=?$/5KA"J16<+'_EHD(W'WS52R\42( MS#4(Q<*YRS8YHHI1I0@_=0JDY35I,VX["UU>#SK$GW5QC%9%YHQ1B"!D445O M#W])'%&3B[(RIM/9"<&JKQ,AYHHK&7NNR.R+NKL911133N!VGAL?\2A/J:T; MC_CUE_W#_*BBOB<1_O3]3Q:O\9^IYU1117VT=D>R%2)"SGBBBIG)IE(WM`M7 MM[K>RYW<<&NM>U'D^9#28` MK`X,C#FN7NKN>\E,EQ*TC'N3117>E8[(125R&BBBF:!1110!>T_5[G3I`T3D MKW0]#736E[8:\NQHS#<>PR#111=HQJQ5KE/4=`:%CD#\ZPI[%HR<$444Y)C-#PW(L-U*KG!8<5U?_`"Q/THHKX_-/]Y.+&*U0\\F_U\G^\?YTRBBO MK*?P(]*.P44450T>A>%H@FGQD]AFL+Q6YGN(_RJ,YHHKHC%)7/DZDVY"*YNYM)(`R=1]:**SJ0C)7:(HR>QGD8.#24452V-V%;> M@C*/]:**SJ;'HY7_`+PBWX@8KIX`/5A7,T44Z>Q>;_[Q\ARJ6-7]/M6^T(Z@ M':<\T44DE4?++8\NII'0Z+4-;2QA4;"96'"]JY:]U">^DS*WRCHHZ"BBIHX: MEAU:FK'/0IQBKHJT445L=`4444`%%%%,"YI^ISZ?(#&QVY^[FNPM;JU\06X$ MB[93P&QU/O113O[MS"M%+WD8.KZ"]I(<8_.L)E*,0>M%%2]&C2E)RCJ1M]XT MJ=#117-'XSV*FN&'4445U'E"@9-3PVY=@!UHHK*3UL4MB&1=LC+Z&FT45H2? "_]D_ ` end